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Abstract 
Background 
The influence of pregnancy, parity, and sex on melanoma outcome is an important 
question as melanoma is one of the few cancers that affect women during their 
childbearing years and is one of the main cancers occurring during gestation. Since 
the 1950s, there have been concerns that pregnancy-associated hormones, 
immunological suppression, and increased lymphangiogenesis might lead to negative 
outcomes for pregnancy-associated melanomas. However, to date there has not been 
conclusive evidence. Additionally, the timing of a pregnancy is of particular 
importance to melanoma survivors of reproductive age. Despite this proposed 
detrimental effect of pregnancy on melanoma outcome overall females have 
demonstrated superior survival rates over males. This advantage cannot be explained 
solely by behavioural factors like earlier diagnosis and management. The role of 
reproductive factors, such as parity and sex hormones, in relation to sex differences in 
melanoma survival has not been fully investigated.  
 
Objectives 
My study objectives were firstly to evaluate the possible effect of a coinciding 
pregnancy on cause-specific death and recurrence of melanomas; secondly to evaluate 
the risk of cause-specific death and recurrence in women who have a pregnancy 
following their melanoma diagnosis; thirdly to evaluate the effect of parity versus 
nulliparity before melanoma diagnosis on cause-specific death; and lastly to evaluate 
the risk of cause-specific death in women with melanomas compared to men 
according to age group and stage of disease. 
 
Methods 
To address my first and second aims I conducted a systematic review and meta-
analysis according to PRISMA guidelines.  Five databases (Cochrane Database, 
MEDLINE, EMBASE, CINAHL, and PUBMED) were searched firstly for studies 
assessing the effect of a coinciding pregnancy on melanoma prognosis and secondly 
for studies assessing the effect of a subsequent pregnancy on the prognosis of a 
previous melanoma. Individual study effect estimates were pooled using the weighted 
average method. To address my third objective, melanoma survival rates were 
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analysed after a 30-year follow-up in a small Queensland cohort of 232 melanoma 
patients diagnosed in 1979-1980 according to sex and parity at time of diagnosis. To 
address my fourth objective, registry-based studies were conducted to compare 
melanoma survival rates between males and females. This was done across two 
population cohorts of melanoma diagnoses between 1995 and 2008 in Australia 
(Queensland Cancer Registry) and the United States (the Surveillance, Epidemiology, 
and End Results Program) analysing outcomes at 10-year follow-up. The patients 
were grouped according to sex, melanoma stage, and patient age at diagnosis.  
Flexible parametric survival models compared survival between groups.  
 
Results  
Meta-analysis of 4 eligible studies demonstrated that a female diagnosed with a 
melanoma during pregnancy has a 56% increased risk of death compared with those 
diagnosed outside of pregnancy, though this was not fully supported by the systematic 
review. The second systematic review and meta-analysis found no firm grounds for a 
melanoma survivor to delay pregnancy.  The pooled estimate for risk of melanoma 
death was 0.81 (95% CI 0.60-1.09). However, given the wide confidence interval 
around the pooled estimate for risk of melanoma death, ill effect of subsequent 
pregnancy cannot be entirely ruled out. The small Queensland cohort study involved 
232 patients grouped according to parity. This exploratory study lacked statistical 
power and matching was not adequate so full evaluation was not feasible. In the 
analysis of two large population cohorts in Australia and USA it was demonstrated 
that the female survival advantage was evident across nearly all melanoma stages, 
including stage 1 melanomas. This advantage was dependent on patient age at 
diagnosis. These findings support overall the importance of host tumour interactions 
in determining melanoma prognosis.  
 
Conclusion  
Across multiple studies, it is shown that sex and reproductive history can affect 
melanoma outcome. A pregnancy coinciding with a melanoma diagnosis in a woman 
has a detrimental influence on survival. Despite this, overall women have a survival 
advantage for melanoma compared to men. The underlying mechanisms are still 
being investigated. 
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Hypotheses 
 
1. Pregnancy coinciding with melanoma in a woman has no influence on the 
course of melanoma (survival rates or disease-free intervals) 
 
2. Melanoma prognosis is not affected by a subsequent pregnancy 
 
3. Melanoma prognosis is not affected by previous pregnancies 
 
4. The survival advantage in females does not vary with age 
 
 
Study objectives  
 
1. To evaluate the effect of pregnancy on cause-specific death and recurrence of 
melanomas two groups are compared in a meta-analysis of available literature: 
women with melanomas occurring during pregnancy (including one-year post-
partum) and women with melanomas occurring outside pregnancy 
 
2. To evaluate the effect of a subsequent pregnancy on cause-specific death and 
recurrence of melanomas two groups were compared in a meta-analysis of 
available literature: women who had a pregnancy after their melanoma diagnosis 
and women who were non-pregnant following their melanoma diagnosis  
 
3. To evaluate the effect of parity on risk of cause-specific death in parous 
women diagnosed with melanoma compared with nulliparous women and men in 
a Queensland cohort 
 
4. To evaluate the risk of cause-specific death and recurrence in women with 
melanomas as compared to men according to melanoma stage and patient age 
across two population cohorts of melanomas diagnosed in Australia and the 
United States 
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CHAPTER 1 
Introduction and Literature Review 
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Cutaneous melanoma is a neoplasm arising in the skin from the malignant 
transformation of melanocytes (1). Risk factors for the development of melanoma 
include skin type 1 or 2 (fair skin, tendency to sunburn), family history of melanoma, 
increased number (>50) and increased size (>5mm) of melanocytic nevi, congenital 
nevi, increased number of dysplastic nevi (>5), and dysplastic nevus syndrome (2-4). 
The main environmental factor increasing the risk of melanoma is intermittent 
exposure to ultraviolet (UV) radiation particularly during childhood (5). 
 
Melanoma is a global public health issue among Caucasian populations with the 
worldwide number of cases increasing at a rate faster than other cancers. Over the 
past decades there has been a steady increase in melanoma incidence (6). There were 
an estimated 160 000 new cases worldwide and an estimated 41 000 deaths in 2002 
(6). In Australia, in 2006 there were 10326 new cases of melanoma diagnosed with 
1279 deaths in 2007 (7). In 2008 there were approximately 200 000 new cases 
diagnosed globally and about 46 000 melanoma related deaths (8). Recent age-
adjusted annual incidence rates for the United States were 22.5 per 100 000 in 2008 
(9) and for the European countries combined was 11.1 per 100 000 in 2012 (10). 
Australia has the world’s highest annual incidence rate of 37 per 100 000 (2008) 
which is 13 times higher than the average global rate (7).  
 
Once a melanoma is diagnosed, its natural course is dependent on the stage of disease. 
This takes into account the extent of spread of the melanoma, tumour thickness, 
mitotic rate, and presence of ulceration. The American Joint Committee on Cancer 
(AJCC) Melanoma Staging Database of over 60 000 patients has determined the 
following survival rates (11). Stage I represents localized thin disease and has a 92-
97% 5-year survival rate and 86-95% 10-year survival rate. Stage II regroups more 
invasive tumours that have not spread from the primary site and has 53-81% 5-year 
survival rate and 40-67% 10-year survival rate. Stage III is reached when lymph 
nodes are invaded at the microscopic or macroscopic level and has a 40-78% 5-year 
survival rate and 24-68% 10-year survival rate. Stage IV is defined by further spread 
to the skin or distant lymph nodes but also to visceral organs such as the lung, liver or 
the brain. It has a 15-20% 5-year survival rate and 10-15% 10-year survival rate. In 
stage IV the prognosis is far better if the metastases have spread to the lymph nodes 
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compared to visceral organs. For all stages combined, melanoma has a 92% 5-year 
survival rate which leads to increased prevalence in the Australian population (12).  
 
Several host-derived factors have been shown to influence melanoma prognosis. 
Indeed, women have significantly better survival rates for melanoma compared to 
men (13-15). An underlying biologic mechanism may have a role. Reproductive 
factors, such as pregnancy and parity, are biologic processes that only women are 
exposed to and so may assist in explaining the improved prognosis for women. 
 
Melanoma incidence during reproductive age 
Melanoma is one of the few cancers that occur with measurable incidence in young 
adults, including women during their childbearing years. Cutaneous melanoma is the 
most common cancer occurring in females aged 17-33 in Australia (12), and aged 20-
29 in the United States (16). The high incidence is reflected in the relatively high 
number of cases observed to occur during pregnancy. Melanoma during pregnancy 
has an estimated incidence of 0.14-2.8 cases per 1000 live births (17, 18). A recent 
Australian population-based study estimated that the incidence of melanoma 
occurring during pregnancy was more than twice that of the general population (19). 
Melanoma accounts for approximately 8% of all malignant neoplasms occurring 
during gestation (20) following cervical and breast cancer (18). In Germany, 1% of 
female melanoma patients were pregnant at the time of diagnosis (21). Melanoma has 
recently been ranked as the leading cause of cancer during pregnancy in both Norway 
(22) and Australia (19). This makes it a significant public health issue affecting a 
variety of medical specialties including Dermatology, Oncology, General Practice, 
and Obstetrics and Gynaecology. 
 
Melanoma during pregnancy  
The influence of pregnancy on the natural history of melanoma has long been debated 
in the literature. The controversy began with a succession of case reports and case 
series that suggested a poorer prognosis for melanomas occurring during pregnancy 
with decreased survival rates (23-28) and shorter disease-free intervals (29, 30). Due 
to their small sample sizes and lack of control for disease stage they only provided 
anecdotal evidence. These findings were not supported after adjustment for disease 
stage and known major prognostic factors such as tumour thickness (20, 26, 31, 32). 
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However these were case- control studies limited in size. Another issue with these 
previous studies has been the variable patient follow-up period. Studies who report 
survival rates of 5-10 years may not identify a potential effect of pregnancy on 
melanoma survival especially in thin melanomas.  
 
There has been a variable definition of “pregnancy-associated” across the studies 
published to date. “Pregnancy-associated” outcomes are consistently described in the 
obstetric literature as during the 9 months of gestation and 12 months post-partum 
(33) which is the definition adopted throughout this thesis. However, there has been a 
wide range of definitions of melanoma in “pregnancy” or “pregnancy-associated” 
melanoma. Authors have defined  “pregnancy-associated” melanoma as melanomas 
diagnosed 3 years pre and post-delivery (34), pregnancies occurring 17 months prior 
to 66 months post melanoma diagnosis (35), and pregnancies occurring within 1 year 
before melanoma diagnosis and 5 years after a melanoma diagnosis (36). Two studies 
included melanomas diagnosed before or during pregnancy in their “pregnant” group 
(37, 38).  It is important for consistent use of the definition of pregnancy-associated 
melanoma to ensure comparisons can be made between studies. 
 
Melanomas diagnosed during pregnancy have been reported to be associated with 
poorer prognostic factors such as thickness and anatomical location. Several studies 
of pregnant women with melanoma have demonstrated increased tumour thickness 
compared with non-pregnant controls (29, 39). Some studies have found that 
melanomas occurring during gestation tend to occur on body sites associated with a 
worse prognosis such as head, neck, and trunk (17, 26, 37, 39, 40). Other studies have 
not found this association (30). These studies had their limitations. It is evident that 
most studies that used matched cases and controls for melanoma prognostic factors 
such as thickness, failed to detect differences in terms of melanoma outcome. In fact, 
if thickness is in general higher in pregnant compared to non-pregnant women 
resulting consequently in poorer outcome, case and control matching for this variable 
will erase potential differences. It is therefore predicted that only large cohorts 
sufficiently representing the entire population will be informative.  
 
There have been two large registry-based studies designed to address this question, 
producing contradictory results (22, 41). A Swedish study analysed 5533 melanomas 
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occurring in women aged 15-45 years between 1958 and 1999 (41). This included 185 
melanomas occurring during gestation. They reported no difference in survival rates 
between their pregnant and non-pregnant groups. The mean melanoma thickness was 
higher in the pregnant group compared to the non-pregnant group overall. This 
difference became significant in the subgroup of women diagnosed with melanoma in 
the 3rd trimester. The length of follow-up was similar in the pregnant group (median 
11.6 years) and the non-pregnant group (median 11.4 years). In contrast, a Norwegian 
study demonstrated an elevated risk (HR=1.52) of cause-specific death in women who 
had melanomas diagnosed during pregnancy compared to non-pregnant women (22). 
This study included a cohort of 4746 women aged 16-49 years who were diagnosed 
with melanoma between 1967 and 2002. This included 160 women who were 
diagnosed with melanoma during gestation. Their mean follow-up time was 11.9 
years in both the pregnant and non-pregnant groups. As both these studies were 
registry-based cohorts their main limitation was missing data. 
  
Neither the 2011 American Academy of Dermatology melanoma guidelines (42) nor 
the 2012 European Dermatology Forum guidelines for melanoma management (43) 
have any recommendations regarding management of melanomas occurring during 
pregnancy. Current clinical practice guidelines for the management of melanoma in 
Australia and New Zealand published in 2008 state that there is no effect of 
pregnancy on melanoma prognosis (44). Meanwhile the debate continues as to 
whether there is a relationship between prognosis of melanoma during pregnancy and 
if so, what are the underlying mechanisms responsible. 
 
Melanoma before pregnancy 
The influence of pregnancy on the prognosis of a previously treated melanoma is an 
important question for melanoma survivors in their childbearing years. There have 
been a handful of case reports, case series, (23, 24, 45) and some larger cohort studies 
(22, 39, 41) that have addressed this question with varied results. Earlier case reports 
raised concerns that a subsequent pregnancy may activate micrometatases from a 
previous melanoma based on the theoretical influence of pregnancy related hormones 
and growth factors (46, 47). Larger cohort studies have not found that a subsequent 
pregnancy affects the outcome of a previously diagnosed melanoma (22, 39, 41). 
Mackie et al (39) assessed a sub group of 85 patients who had been diagnosed with 
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melanoma prior to becoming pregnant. They were compared to 143 patients who had 
completed all pregnancies prior to the diagnosis of melanoma. They found no 
difference in survival rates or disease-free intervals between the two groups (39). A 
large Swedish national cohort study assessed 966 women who had pregnancies after 
their melanoma diagnosis and compared them to 4567 women with melanoma who 
did not have subsequent pregnancies (41). They found no difference in survival rates 
between the two groups. However, they did not analyse the rates of recurrence or risk 
of further melanoma diagnoses. Stensheim et al reported survival rates of 3949 
women who were nulliparous or had their melanoma diagnosis after pregnancy and 
compared them to 797 women who had a melanoma diagnosis before pregnancy (22). 
They demonstrated a trend towards a reduced risk of cause-specific death in women 
who had pregnancies after their melanoma diagnosis. Overall the existing data 
suggest that pregnancy does not influence the recurrence of a previous melanoma. 
 
Melanoma after pregnancy 
The influence of past gestations on melanoma prognosis has rarely been addressed in 
the literature.  A recent study further showed that nulliparity was associated with 
increased risk for disease-specific death when adjusted for age, localisation, stage, 
and Breslows thickness (34). Women with at least one pregnancy had improved 
survival rates compared to nulliparous women. Overall these studies suggest that prior 
gestation seems to influence the outcome of melanoma however, to date this has not 
been addressed in a large cohort study with adjustment for known prognostic markers. 
 
Melanoma outcome differs by sex  
Melanoma appears to behave differently depending on the sex of the patient. A 
registry-based study in Munich analysed 11774 cases of melanoma (13). They found 
that females had significantly higher 10-year survival rates compared to males in all 
stages of melanoma.  Females also had a decreased risk of lymph node and visceral 
metastases and even after diagnosis of lymph node metastases there was a lower risk 
of developing distant metastases. Joose et al conducted a further study analysing the 
difference in survival rates between males and females in 2672 patients with stage 1 
or 2 melanoma (15). They demonstrated that females had a highly consistent and 
independent advantage of approximately 30% in overall survival rates, disease-free 
interval, time-to-lymph node and distant metastases. They postulated a protective 
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factor in females responsible for the difference in survival rates though they did not 
speculate on what it might be. Among the many factors that differ between men and 
women that might influence melanoma outcome, gestation and its associated 
physiological changes need to be assessed, in particular since pregnancy has long 
been suspected to influence the course of melanoma. 
 
Research question development 
Due to the natural history of melanoma with its relatively long latent period, long-term 
follow-up is required to accurately predict the effect of pregnancy, parity, and sex on 
prognosis. In this study, I propose to evaluate the influence of pregnancy, parity, and 
sex on melanoma outcome. The study design allows for analysis of the current 
literature as well as long-term follow up of a large population group to more 
accurately assess melanoma-associated mortality.  
 
Overall these previous studies bring up a series of questions that I have aimed to 
answer in this document: 
 
1. Does a pregnancy coinciding with melanoma in a woman influence the course of 
that melanoma (survival rate or disease-free interval)? 
 
2. Is melanoma prognosis in a female affected by a subsequent pregnancy? 
 
3. Is melanoma prognosis in a female affected by previous pregnancies? 
 
4. Does the survival advantage in females vary with age? 
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CHAPTER 2 
Increased mortality for pregnancy-associated 
melanoma: A systematic review and meta-
analysis 
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An initial question following my literature review was to address the controversy 
surrounding the field. The effect of a coinciding pregnancy on the natural course of 
melanoma has long been debated in the literature. While many studies were published 
on this subject there was significant heterogeneity in their design, length of follow-up, 
statistical analysis, and definition of pregnancy. It is plausible that pregnancy may 
have an effect on the development and progression of melanoma due to pregnancy-
associated hormones, growth factors, and immunosuppression. However, studies to 
date have been contradictory with no clear answer presented. This required a more 
rigorous approach to the literature to understand the state of the evidence to address 
this question. Accordingly, I decided to conduct a systematic review and meta-
analysis of the literature to date. 
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Abstract 
Background: Among women pregnancy-associated melanomas may have a poorer 
prognosis than other melanomas but evidence is inconsistent. We conducted a 
systematic review and meta-analysis to assess the effect on melanoma outcome of a 
coinciding pregnancy. 
 
Objective: To conduct a systematic review and meta-analysis of risk of death from, 
or recurrence of, pregnancy-associated melanomas compared with other melanomas 
in women of reproductive age.  
 
Methods: Cochrane (1996-2013), MEDLINE (1950-2013), EMBASE (1966-2013), 
CINAHL (1982-2013), and PUBMED (1951-2013) databases were searched for 
studies assessing the risk of death and recurrence in pregnancy-associated melanomas. 
Eligible studies investigated melanoma outcomes in women with pregnancy-
associated melanomas (diagnosed during pregnancy or in the 12 months following 
pregnancy), included a comparison group and reported measures of risk of melanoma 
death or disease-free survival. Eligible study designs were cohort studies of women of 
childbearing age with confirmed diagnoses of cutaneous melanoma. Individual study 
effect estimates were pooled using the weighted average method. Studies that did not 
report a quantitative estimate were summarised narratively. 
 
Results: Of 304 citations identified, 14 studies met the inclusion criteria, with 
assessed outcomes being melanoma death (7), recurrence (3), or both (4). Pooled 
estimates of mortality risk from 4 studies showed increased risk of melanoma death 
after adjustment for patient age and stage of melanoma (pHR 1·56, 95% CI 1·23-1·99) 
for pregnancy-associated melanoma compared with other melanomas.  
 
Conclusion: Based on limited quantitative evidence, pregnancy-associated 
melanomas appear to have poorer outcomes than other melanomas. 
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Introduction 
It is a matter of debate whether pregnancy-associated melanomas have worse 
outcomes than other melanomas in women. Concern was first raised by case reports 
in the 1950s suggesting intercurrent pregnancy reduced survival (23-28) or shortened 
disease-free intervals (29, 30).  Several case-control studies of melanoma conducted 
in the 1980s showed no influence of intercurrent pregnancy after adjustment for 
disease stage and other prognostic factors (20, 39, 45, 48). More recently, two large 
registry-based cohort studies have produced contradictory results with a Swedish 
study reporting no difference in survival rates between pregnant and non-pregnant 
women diagnosed with melanoma (41) while a Norwegian study reported increased 
risk of melanoma death in the pregnant group (22). 
 
Whether pregnancy influences melanoma prognosis is an important question since 
melanoma is one of the few cancers, along with cervical, breast, and haematological 
malignancies (22) that occurs relatively commonly in young women during their 
childbearing years (12, 16). Melanoma is the leading cancer during pregnancy in 
Norway (22) and Australia (19). In a German study, 1% of female melanoma patients 
(1983-1989) were pregnant at the time of diagnosis (21) and a recent Australian 
population-based study estimated the incidence of melanoma occurring during 
pregnancy to be more than twice that in the general female population (19). 
 
To improve our understanding of the possible influence of an associated pregnancy on 
melanoma outcome, we conducted a systematic review of existing evidence and 
compared the prognosis of women with pregnancy-associated melanoma with the 
prognosis of those diagnosed outside pregnancy.  
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Methods:  
Search strategy  
We conducted a meta-analysis and systematic review in accordance with the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines 
(46). Searches of the Cochrane Database (1996-2013), MEDLINE (1950-2013), 
EMBASE (1966-2013), CINAHL (1982-2013), PUBMED (1951-2013) were 
conducted using the MESH terms “Pregnancy”, “Prognosis”, and “Melanoma”. 
Reference lists of the articles selected for inclusion were reviewed for additional 
relevant papers. The search was limited to studies reported in the English language. 
 
Selection of Studies and Extraction of Data 
Studies were identified as eligible for review if they investigated melanoma outcomes 
in pregnant women, if they included a comparison group and if outcome measures 
reported were risk of melanoma death or disease-free survival. Studies were included 
if their pregnancy-associated group had their melanomas diagnosed either during 
pregnancy or up to 12 months post-partum. This was designed to minimise any 
confounding effect that pregnancy-related hormones in the post-partum period could 
have on the prognosis of the melanoma and is consistent with obstetric definitions of 
“pregnancy-associated” outcomes (33).  Eligible study designs were population-, 
clinical- and hospital-based cohort studies of females of childbearing age with 
histological confirmed diagnoses of cutaneous melanoma. Comparison groups 
included nulliparous women or women who had melanoma diagnosed outside 
pregnancy (non-pregnant). If two papers reported results based on the same patient 
population, the study with the longest follow-up period and most complete data was 
included. Studies were included in the meta-analysis if they reported a hazard ratio 
(HR) with a 95% confidence interval (CI) and results of studies that did not report a 
HR were summarized narratively.  
 
Data synthesis 
Two reviewers (LB, LK) independently extracted data using a customised data 
extraction form. The following information was included for each study: year of 
publication, geographic location, study design, melanoma characteristics (American 
Joint Committee on Cancer (AJCC) stage (11) and histological type), patient 
characteristics (age at diagnosis, relationship between pregnancy and melanoma 
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diagnosis), duration of follow-up, definition of pregnancy, summary effect estimates 
(including crude and adjusted odds ratios and hazard ratios with 95% CIs), study 
outcomes (survival rates, disease-free intervals), matching of the patient groups, and 
details on adjustment for confounding variables. If the groups were not matched, 
authors’ comments on the comparability of the patient and melanoma characteristics 
between the groups were noted. Inconsistencies were reviewed until consensus was 
achieved. For studies that did not present an effect estimate we extracted data on their 
outcome measures including risk of melanoma death or melanoma survival rates, and 
disease-free survival rates. Design weaknesses or potential sources of bias were noted. 
 
Statistical analysis 
Individual study estimates were pooled using the weighted average method where the 
weight of each study is inversely proportional to the study variance. We determined a 
priori to conduct random effects meta-analysis (49) in the presence of statistically 
significant heterogeneity, assessed using the Q statistic (50) (significance level at 
P<0·05), with inconsistencies quantified using the I2 statistic (51). 
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Results 
Our search strategy yielded 304 articles of which 136 were duplicates (Fig 1). The 
titles and abstracts were then examined for eligibility, which excluded 154 studies. 
We identified 14 studies (20, 22, 26, 29, 30, 32, 39, 41, 45, 48, 52-55) that met the 
inclusion criteria for the systematic review (Fig 1). Nine studies were retrospective 
clinical cohorts (20, 29, 30, 32, 39, 45, 48, 52, 53) and five were population-based 
cohort studies (22, 26, 41, 54, 55) (Table 1).  
 
Eleven studies compared the risk of melanoma death in women who had melanomas 
diagnosed during pregnancy to the risk in those diagnosed outside pregnancy (20, 22, 
26, 29, 32, 39, 41, 45, 52, 54, 55). The number of pregnant women with melanoma in 
these studies ranged from 10 to 412. All studies except one (45) had follow-up 
periods of at least 5 years (range 5 to 20 years) (Table 1). Six of the 11 studies 
involved only women with primary melanoma with no known metastases (number of 
pregnancy-associated melanoma cases ranged from 23 to 185) (20, 29, 39, 41, 45, 52) 
and 5 of the 6 observed no significant difference in melanoma survival between 
pregnant and non-pregnant groups (Table 2). Of the other 5 studies (22, 26, 32, 54, 
55) where survival was examined in women with all stages of melanoma (number of 
pregnancy-associated melanomas ranging from 12 to 412), 3 found no significant 
difference by pregnancy status after accounting for stage at diagnosis (Table 2).  One 
study that found an increased risk of death in 306 women with pregnancy-associated 
melanomas assessed all-cause rather than melanoma-specific mortality (54), but the 
vast majority (86%) of deaths were due to melanoma.  
 
Of these 11 studies reporting risk of melanoma death, 4 reported quantitative 
estimates (22, 39, 41, 54) which when pooled gave a significantly elevated risk of 
melanoma death (pHR 1·56 (95% CI 1·23-1·99)) in women whose melanomas were 
diagnosed during pregnancy compared with women whose melanomas occurred 
outside of pregnancy (Fig 2). There was no evidence of heterogeneity (p=0·410) or 
publication bias (Begg p=0·308; Egger p=0·301).  
 
Seven studies assessed risk of melanoma recurrence in women following a melanoma 
diagnosed during pregnancy (20, 26, 29, 30, 45, 48, 53).  Of these 7, 4 reported no 
significant difference in disease-free survival for women with melanomas diagnosed 
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during compared with outside pregnancy (20, 26, 45, 48). There was a significantly 
increased risk of melanoma recurrence in women with localised melanomas 
diagnosed during pregnancy seen in 2 studies (29, 32) while another study (53) 
reported a non-significantly reduced recurrence of localised melanomas diagnosed in 
pregnancy (Table 2). 
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Discussion 
Meta-analysis of the available quantitative data adjusted for other prognostic factors, 
showed a 56% increased risk of mortality from pregnancy-associated melanomas 
compared with other melanomas in women of reproductive age. Our systematic 
review of the literature also identified several other studies of survival after 
pregnancy-associated melanoma but their results were not fully quantified so could 
not be included in the meta-analysis. Overall their reported results did not support the 
pooled finding, but most were based on relatively few women with pregnancy-
associated melanoma with limited follow-up, so their power to detect a possible 
association of pregnancy with survival outcome is difficult to assess.   
 
It is plausible that pregnancy-associated melanomas may have poorer outcomes than 
other melanomas because pregnancy is a state of reduced cellular immunity (56). This 
is to prevent rejection of the fetus (56) however, this relative suppression of the host 
immune system could enhance the growth of melanomas during pregnancy. Increased 
levels of myeloid suppressor cells and decreased natural killer cell cytotoxicity have 
been shown to mediate pregnancy-related immunosuppression resulting in enhanced 
tumour growth and metastases (57). Additionally, immunosuppressed patients who 
are not pregnant have been shown to have an increased risk of melanoma death 
regardless of stage at diagnosis (58, 59). 
 
Increased lymphangiogenesis occurring during pregnancy also could worsen the 
outcome of a coinciding melanoma. After a primary melanoma develops, the 
prognosis worsens with the development of lymphatic metastases. Increased 
lymphangiogenesis has been reported as the strongest independent predictor of 
sentinel node invasion by melanoma (60). Tumour lymphangiogenesis is an important 
prognostic factor in melanoma independent of tumour thickness (61) and pregnancy-
related increased lymphangiogenesis has been shown to result in increased melanoma 
metastases (62, 63). There may also be a deleterious effect of pregnancy-related 
hormones on melanoma (46, 64), although estrogen (65) and progesterone receptors 
(66) on melanoma cells have not been established as directly affecting prognosis. 
Treatment of melanoma with Tamoxifen has not shown any benefit (67, 68) 
suggesting that if melanoma progression is linked to estrogens, it is not a strong 
association.  
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This systematic review was limited by the varying quality of the studies that have 
addressed the topic of prognosis of pregnancy-associated melanoma. Studies with 
small sample sizes and with shorter follow-up (5 to 10 years) may have been unable 
to detect pregnancy-related changes in survival if they are present, especially for 
localised melanomas with high 10-year survival rates (11, 14). Their non-inclusion in 
the pooled analyses could have biased the resulting pooled estimates towards poorer 
summary outcome. Important prognostic factors like patient age were often not taken 
into account in those reviewed studies which could not be included in meta-analysis 
due to lack of quantitative estimates. One large study (N=2346) (55), despite 
reporting an effect estimate did not include the confidence interval, and therefore was 
not eligible for meta-analysis.  
 
The few studies included in the meta-analysis were themselves limited by 
incompleteness of melanoma outcome data ascertained through cancer registries (69). 
Two studies (22, 41) lacked baseline prognostic information about tumour thickness 
for a proportion of patients, though both reported no differences in the baseline 
characteristics and survival rates compared with the patients whose tumour thickness 
data were available, and concluded the missing data did not bias observed results. 
Furthermore we were unable to assess the risk of recurrence of melanomas diagnosed 
in pregnancy due to a lack of adequate published data.  
 
In conclusion, there is a paucity of available quantitative evidence regarding the 
important question of recurrence and death in women with pregnancy-associated 
melanomas.  Larger population-based studies with long-term follow-up would add 
value to the existing body of evidence. This meta-analysis demonstrated that 
pregnancy-associated melanomas have higher mortality than other melanomas 
supporting additional attention to the diagnosis and management of melanoma in 
women during or immediately after pregnancy 
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Figure 1: Article selection: Systematic review of literature using PRISMA guidelines 
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Reported!same!patient!population!(1)! Different!definition!of!“pregnancy”!(4)! Not!cutaneous!melanoma!(1)!Case!control!or!series!(22),!letter!to!editor!(9),!or!review!article!(42)!
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Figure 2: Risk of melanoma death in pregnancy-associated melanomas 
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Table 1: Study characteristics 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Houghton 
et al 1981 
USA(26) 
Registry 
Based Cohort 
Study 
Connecticut 
Tumour 
Registry 
1950-
1954, 
1960-
1964, 
1970-
1974 
5 years 187 Pregnant 
(12) 
 
 
1. Non 
pregnant non-
matched 
(175) 
2. Non 
pregnant 
matched 
controls (24) 
Pregnant at 
time of 
diagnosis 
 
All stages 
Local: 87% 
pregnant 67% 
non-pregnant 
88% 
 
Regional: 10% 
pregnant 17% 
non-pregnant  
10% 
 
Distant: 3% 
-pregnant 16% 
-non-pregnant 
2% 
 
Sutherland 
et al 1983 
USA(52) 
Retrospective 
clinical 
cohort study 
Records from 
The 
department of 
surgery at 
Tulane 
University 
School of 
Medicine 
1957-
1983 
5 years 30 Pregnancy 
associated 
(18) 
 
 
1. Melanoma 
before 
pregnancy 
(12) 
Melanoma 
arising during, 
or stimulated 
by or is 
diagnosed 
during, the 
course of 
pregnancy 
Stage 1: 83% 
Pregnancy 
associated 
83% 
Melanoma 
before 
pregnancy 
83% 
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Table 1 continued 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Sutherland 
et al 1983 
USA 
Cont…. 
        Stage 2: 17% 
Pregnancy 
associated 
17% 
Melanoma 
before 
pregnancy 
17% 
Reintgen et 
al 1985 
USA(29) 
Retrospective 
computer-
aided study 
Duke 
University  
Cancer 
Center. 
1972-
1983 
5 years 1023 Pregnant 
(58) 
 
 
1. Non-
pregnant 
within 5 
years of 
melanoma 
(585) 
Pregnant at 
time of 
diagnosis 
 
Stage 1 
 
McManam
ny et al 
1989 
UK(45) 
Retrospective 
clinic-based 
cohort study 
Computerised 
melanoma 
register and 
follow-up 
questionnaire 
1967-not 
specified 
2mths-
20yrs 
290 Pregnant 
(23) 
 
 
1. Non 
pregnant at 
time of 
diagnosis or 
after 
diagnosis 
(243) 
Pregnant at 
time of 
diagnosis 
 
Stage 1 
Wong et al 
1989 
USA(20) 
Retrospective 
clinic-based 
cohort study 
Melanomas 
treated at 
Surgical 
Oncology at 
UCLA 
1971-
1986 
5 years 132 Pregnant 
(66) 
 
 
1. Non 
pregnant (66) 
Pregnant at 
time of 
diagnosis 
 
Stage 1 
 
 
! 41 
Table 1 continued 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Slingluff et 
al 1990 
USA(30) 
Retrospective 
clinic-based 
cohort study 
Patients at 
Melanoma 
Clinic 
Not 
specified 
10 
years  
167 Pregnant 
(88) 
 
 
1. Non 
pregnant (79) 
Pregnant at 
time of 
diagnosis 
 
Stage 1  
 
Mackie et 
al 1991 
UK(39) 
Retrospective 
clinic-based 
cohort study 
WHO 
melanoma 
program 
study 
Not 
specified 
20 
years  
388 Pregnant 
(92) 
 
 
1. Melanoma 
between 
pregnancies 
(68) 
Pregnant at 
time of 
diagnosis. 
Included 
miscarriages/ 
terminations 
 
Stage 1 
Travers et 
al 1995 
USA(53) 
Retrospective 
hospital 
based cohort 
study 
Massachusetts 
General 
Hospital 
Pigmented 
Lesion Clinic 
Not 
specified 
5 years 465 Pregnancy 
associated 
(45) 
 
 
1. Non-
pregnancy 
associated 
(420) 
Diagnosis 
during 
pregnancy and 
up to 1 year 
post-partum 
Stage 1 
Daryanani 
et al 2003 
Netherlands
(48) 
Retrospective 
clinic-based 
cohort study 
University 
Medical 
Center 
Groningen 
1965-
2001 
10 
years 
414 Pregnant 
(46) 
 
 
1. Non 
pregnant 
(368) 
Pregnant at 
time of 
diagnosis 
 
Stage 1: 56% 
-pregnant 52% 
-non pregnant 
57% 
 
Stage 2: 44% 
-pregnant 48% 
-non pregnant 
43% 
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Table 1 continued 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Lens et al 
2004 
UK(41) 
Retrospective 
population 
based cohort 
Swedish 
National and 
Regional 
Registries 
Jan 01 
1958- 
Dec 31 
1999 
Mean 
12.9 
years 
5533 Pregnant 
(185) 
 
 
1. Non-
pregnant 
(5348) 
 
Pregnant at 
time of 
diagnosis. 
Pregnancy 
terminated by 
delivery of 
child. No data 
on 
miscarriages 
or abortions 
Stage 1 
 
O'Meara et 
al 2005 
USA(55) 
Retrospective 
population 
based cohort 
Data linkage: 
California 
Office of 
State-wide 
Health 
Planning and 
Development 
and the 
California 
Cancer 
Registry  
1991-
1999 
11 
years 
2346 Pregnant 
412 (338) 
 
 
1. Non 
pregnant 
2451 (2008) 
20 weeks 
gestation – 
1year 
postpartum 
 
All stages 
(Localised) 
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Table 1 continued 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Silipo et al 
2006 
Italy(32) 
 
Case control 
study 
Melanoma 
database at 
Dermatologic
al Institute 
Rome 
1991-
2000 
5 years 40 Pregnant 
(10) 
 
1. Non 
pregnant (30) 
Pregnant at 
time of 
diagnosis 
All stages 
In situ: 15% 
-pregnant 10% 
-Non-pregnant 
17% 
 
Stage 1: 50% 
-pregnant 40% 
-Non-pregnant  
53% 
 
Stage 2: 28% 
-pregnant 30% 
-Non-pregnant  
27% 
 
Stage 3: 5% 
-pregnant 10% 
-Non-pregnant  
3% 
 
Stage 4: 2% 
-pregnant 10% 
-Non-pregnant  
0% 
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Table 1 continued 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Stensheim 
et al 2009 
Norway 
(22) 
Retrospective 
Population 
based cohort 
study 
Data linkage 
between the 
Cancer 
registry and 
the medical 
birth registry 
of Norway  
1967-
2002 
Median 
11.9 
years 
4647 Pregnant 
(160) 
 
1. Non-
pregnant 
(nulliparous 
or no 
pregnancies 
at or after 
diagnosis) 
(4460) 
 
Diagnosed 
within the 
same month 
as their last 
menstruation 
until the date 
of delivery.  
 
All stages 
Localised 
pregnant 89% 
non-pregnant 
89% 
 
Regional 
pregnant 2% 
non-pregnant 
1% 
 
Distant 
pregnant 2% 
non-pregnant 
2% 
 
Unknown 
-pregnant 7% 
-non-pregnant 
9% 
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Table 1 continued 
Reference Study design Population 
source 
Time 
period 
Follow-
up 
period 
N 
cases 
Primary 
group  
(N cases) 
Comparison 
group/s 
(N cases) 
Definition 
of 
pregnancy 
or 
pregnancy 
associated 
Melanoma 
stages 
included 
Moller et al 
2013 UK 
(54) 
Retrospective 
registry based 
cohort 
Data linkage 
between The 
national 
cancer 
registration 
and hospital 
discharge 
data  
1998-
2007 
Max 11 
years 
1228 Pregnancy 
associated 
diagnosis 
(306) 
 
 
1. Childbirth 
1-2 yr before 
melanoma 
diagnosis 
(267) 
2. Childbirth 
2-3 yr before 
melanoma 
diagnosis 
(225) 
3. Childbirth 
3-4 yr before 
melanoma 
diagnosis 
(229) 
4. Childbirth 
4-5 yr before 
melanoma 
diagnosis 
(201) 
Pregnancy 
associated:  
Childbirth 0-1 
yr before 
melanoma 
All stages 
72% had 
information on 
TNM stage 
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Table 2: Study results 
Reference Follow-
up 
period 
Statistical 
analysis 
Risk of melanoma death 
(patient group, N cases) 
Risk of recurrence 
(patient group, N cases) 
Adjustment for 
confounding factors 
Houghton et 
al 1981 USA 
(26) 
5 years Fisher exact 
test 
Melanoma survival rate 
Pregnant (12) 55% 
 
Non pregnant matched controls (24) 
58% 
 
(Non pregnant non-matched (175) 
83%) 
 
Pregnant (12) 41.7% 
 
Non pregnant non-
matched (175) 68.0% 
 
 
Matched for Age, site, and 
stage 
-survival analysis only 
Sutherland et 
al 1983 USA 
(52) 
5 years None Melanoma death rate 
Pregnancy associated (18) 55.6% 
 
Melanoma before pregnancy (12) 
20% 
 
NA None 
Reintgen et 
al 1985 USA 
(29) 
5 years Multivariate 
regression 
analysis 
Melanoma death rate 
Pregnant (58) 20.7% 
 
Non-pregnant within 5 years of 
melanoma (585) (control group) 
17.1% 
 
Pregnant (58) 37.9% 
P=0.04 
 
Non-pregnant within 5 
years of melanoma (585) 
(control group) 29.2% 
 
Clark's Level, ulceration, 
and tumor thickness. 
 
McManamny 
et al 1989 
UK (45) 
2mths-
20yrs 
Mantel Cox 
statistic  
Melanoma death rate 
Pregnant (23) 26% (p=0.28) 
 
Non pregnant at time of diagnosis or 
after diagnosis (243) (reference 
group) 13% 
 
Pregnant (23) 27% 
(p=0.44) 
 
Non pregnant at time of 
diagnosis or after 
diagnosis (243) 
(reference group) 20% 
None  
No difference found 
between anatomical site 
and thickness between 
groups 
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Table 2 continued 
Reference Follow-
up 
period 
Statistical 
analysis 
Risk of melanoma death 
(patient group, N cases) 
Risk of recurrence 
(patient group, N cases) 
Adjustment for 
confounding factors 
Wong et al 
1989 USA 
(20) 
5 years None Melanoma survival rate 
Pregnant (66) 86% 
 
Non pregnant (66) 92% 
 
Pregnant (66) 74% 
 
Non pregnant (66) 82% 
 
Matched for tumour 
invasiveness, anatomic 
distribution of primary 
lesions, and 
histopathological features. 
Slingluff et 
al 1990 USA 
(30) 
10 
years  
Kaplan 
Meier 
analysis  
NA Pregnant (88) 50% 
(p=0.039) 
 
Non pregnant (79) 
(reference group) 67% 
Site, thickness, and Clarks 
level  
Age matched groups 
 
Mackie et al 
1991 UK 
(39) 
20 
years  
Hazards 
ratio 
Pregnant (92) HR 1.30 (CI 0.54-
3.15), p=0.56 
 
Melanoma between pregnancies (68) 
(reference group) HR 1.0 
 
NA Site and tumour thickness 
Travers et al 
1995 USA 
(53) 
5 years Odds ratio NA Pregnancy associated 
(45) 0.44 (CI 0.17-1.11), 
p=0.08 
 
Non-pregnancy 
associated (420) 1.0 
Tumour site, histological 
type, age at diagnosis, and 
tumour thickness 
 
Daryanani et 
al 2003 
Netherlands 
(48) 
10 
years 
Kaplan-
Meier 
analysis 
NA Pregnant (46) 
-stage 1 88% (p=0.6541) 
-stage 2 67% (p=0.7322) 
 
Non pregnant (368) 
(control group) 
-Stage 1 86% 
-Stage 2 73% 
Matched for age, gender, 
and AJCC stage 
! 48 
Table 2 continued 
Reference Follow-
up 
period 
Statistical 
analysis 
Risk of melanoma death 
(patient group, N cases) 
Risk of recurrence 
(patient group, N cases) 
Adjustment for 
confounding factors 
Lens et al 
2004 UK 
(41) 
Mean 
12.9 
years 
Hazards 
ratio 
Pregnant (185) 
HR 1.08 (CI 0.60-1.93), p=0.804 
 
Non-pregnant (5348) (reference 
group) HR 1.0 
NA Breslow thickness, tumor 
site, Clark’s level, and age.  
O'Meara et al 
2005 USA 
(55) 
11 
years 
Kaplan 
Meier 
 
Hazard ratio 
i) Melanoma survival rates for 
localised melanoma (Kaplan Meier) 
Pregnant (303)  
(p=0.16) 
Non pregnant (1799) (reference 
group) 
 
ii) Risk of melanoma death all stages 
Pregnant (412) 
-Diagnosed 0-9/12 prior to and at 
delivery: HR 0.79 (P=0.570) 
-Diagnosed 1yr post-partum: HR 
0.58 (P=0.162) 
Non pregnant (2451) HR 1.0 
NA  
 
 
 
 
 
 
ii) Controlled for age, race, 
disease stage, and tumour 
thickness (all stages) 
 
 
 
 
Silipo et al 
2006 Italy 
(32) 
5 years Exact 
Fisher test 
Melanoma death rate 
Pregnant (10) 10% 
 
Non pregnant (30) 6.67% 
 
NA 
 
Matched for age, 
localisation, histological 
type, and AJCC stage 
 
Stensheim et 
al 2009 
Norway (22) 
Median 
11.9 
years 
Hazards 
ratio 
Pregnant (160) 
HR 1.52 (CI 1.01-2.31), p<0.05 
 
Non-pregnant (nulliparous or no 
pregnancies at or after diagnosis) 
(4460) (reference group) 1.0 
NA Age at diagnosis, initial 
extent of disease, and 
diagnostic periods 
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Table 2 continued 
Reference Follow-
up 
period 
Statistical 
analysis 
Risk of melanoma death 
(patient group, N cases) 
Risk of recurrence 
(patient group, N cases) 
Adjustment for 
confounding factors 
Moller et al 
2013 UK 
(54) 
Max 11 
years 
Hazards 
ratio 
Pregnancy associated diagnosis (306) 
HR 1.92 (CI 1.32-2.79) 
 
NA Age and TNM stage 
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General Discussion 
After careful consideration and analysis of the evidence published to date I have solid grounds 
showing that women who have melanomas occurring during pregnancy have a higher risk of 
melanoma death. The possible mechanisms involved are still under investigation. This does 
summarise the existing evidence, however this was limited to four papers eligible for inclusion in 
meta-analysis. These papers included analysis of predominately early stage disease, which raises 
the possibility of an even higher risk of death in more advanced melanomas.  
 
At the time of acceptance of our paper an additional study addressing this question was published 
(70). This was a population-based cohort study that compared mortality between women who had 
their melanomas diagnosed during pregnancy and up to 2 years post-partum with women who were 
non-pregnant at the time of their melanoma diagnosis. A total of 6857 women aged 15-44 years 
with cutaneous melanoma diagnosed between 1963-2009 were included. They reported no 
difference between the two groups (HR 1.09, 95%CI 0.83-1.42). The data were retrieved from the 
National Swedish Cancer Register which was also the data source used for a study included in our 
meta-analysis (41) with overlap of dates of melanoma diagnoses included in analysis. However, 
because the definition of pregnancy-associated melanomas of the most recent study (70) included 
diagnosis during pregnancy and two years post-partum, which was not in keeping with our study 
inclusion criteria (viz. pregnancy and one-year post-partum, which reflects obstetric definitions) 
(33), this study was excluded from the meta-analysis. 
 
Pregnancy-associated melanomas have been reported to be associated with increased tumour 
thickness. Of the 4 studies included in the meta-analysis, 2 reported an increased Breslow thickness 
in the pregnant group (39, 41). Lens et al demonstrated a non-significant increased mean melanoma 
thickness in the pregnant group compared to the non-pregnant group overall (41). This difference 
was significant in the subgroup diagnosed with melanoma in the 3rd trimester. Mackie et al reported 
that pregnancy was associated with shorter disease free survival, increased rates of melanoma death, 
and increased Breslow thickness. Once controlled for thickness, there was no difference in 
melanoma death or recurrence for women who had melanomas diagnosed during pregnancy 
compared to other groups (39). In support of these studies, a recent population-based Australian 
report from NSW largely confirmed the increased thickness of melanoma observed during 
pregnancy (71). Finally, Stensheim et al and Moller et al found no difference in thickness between 
their pregnancy-associated and non-pregnant groups (22, 54). However, one of their limitations was 
incomplete data in this regard. These studies did adjust for known prognostic factors including 
thickness. It can be debated that adjusting for thickness may be eliminating the underlying 
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mechanism or reason (such as delayed diagnosis and excision due to perceived foetal risks) by 
which pregnancy-associated melanomas have a worse prognosis.” 
 
International melanoma management guidelines should aim to provide advice for clinicians 
managing this group of women. Current guidelines either provide no recommendations for 
management of melanomas occurring during pregnancy (42, 43) or state that there is no effect of 
pregnancy on melanoma prognosis (44). However, these guidelines were published before two of 
the four studies included in meta-analysis were conducted. In light of more recent evidence and its 
contribution to the pooled estimate demonstrating increased risk of death in women with pregnancy 
associated melanomas I suggest a review of the current melanoma management guidelines. Despite 
the paucity of evidence a precautionary attitude should prevail. Women with melanoma risk factors 
should undergo a thorough full skin examination before a planned pregnancy or immediately upon 
the diagnosis of pregnancy until the end of the first year post-partum. Regular full skin examination 
during this period can be incorporated into routine antenatal and post-natal care of the patient. 
When following these women it is also important to recognise this patient group as at increased risk 
of melanoma death. 
! 52 
 
 
 
 
 
 
 
CHAPTER 3  
Does pregnancy following a diagnosis of melanoma 
affect prognosis?   
A systematic review and meta-analysis 
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Having established that a coinciding pregnancy can affect the outcome of melanoma, an important 
question for melanoma survivors is whether a subsequent pregnancy is likely to affect their 
survival. Melanoma is the most common cancer occurring during childbearing years thus is a 
serious health problem whose outcomes affect both the patient and their families when planning for 
future pregnancies. Current clinical practice guidelines for the management of melanoma in 
Australia and New Zealand (published 2008)(44) recommend that women avoid pregnancy for two 
to five years following a melanoma diagnosis. This is precautionary advice with scarce evidence to 
date to support this guideline. The question is raised; does a subsequent pregnancy affect the 
prognosis of a previously diagnosed melanoma? To address this question I conducted a systematic 
review and meta-analysis of the literature to date. This result will assist the medical community in 
providing advice on family planning for women who are melanoma survivors.  
 
 
Pregnancy 
Melanoma 
diagnosis 
Relationship between melanoma diagnosis and pregnancy 
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Abstract  
Background 
Whether pregnancy after diagnosis of melanoma affects a woman’s prognosis is unknown. We 
conducted a systematic review and meta-analysis to answer this question.  
 
Methods 
Five databases (Cochrane Database, MEDLINE, EMBASE, CINAHL, and PUBMED) were 
searched for studies assessing the effect of subsequent pregnancy on risk of melanoma death or 
recurrence. We collated all longitudinal studies of women of childbearing age diagnosed with 
incident melanoma that compared melanoma outcomes among those who became pregnant after the 
diagnosis and those who did not. Individual study effect estimates were pooled when available 
using the weighted average method, and other findings were summarised narratively. 
 
Findings 
Of 304 citations identified, 5 studies met inclusion criteria. All 5 assessed melanoma death and 2 of 
the 5, recurrence. There was no significant effect of subsequent pregnancy on melanoma mortality 
after 11-20 years of follow-up (pooled HR 0·81, 95% CI 0·60-1·09) and no significant differences in 
melanoma recurrence.  
 
Conclusion 
Current evidence does not support the hypothesis that pregnancy subsequent to successful treatment 
of melanoma worsens prognosis. However relevant data are sparse, suggesting a precautionary 
approach is warranted regarding childbearing advice to melanoma survivors.  
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Introduction 
Melanoma is one of the few cancers that occur with measurable incidence in young adults and thus 
a material proportion of women are affected during their childbearing years. Indeed cutaneous 
melanoma is the most common cancer occurring in females aged 20-29 years in the United States 
(16), and in those aged 17-33 years in Australia (12). 
 
The question of how the natural history of a previously diagnosed melanoma may be affected by a 
woman’s subsequent pregnancy has been debated in the literature since the 1950s.  A clear answer 
has not been established, yet the question is of particular importance to women who are melanoma 
survivors in their childbearing years. Early case series (23, 24) suggested that a subsequent 
pregnancy might activate melanoma micrometastases, based on the theorized influence of 
pregnancy-related hormones and growth factors on melanoma development and recurrence (46, 47). 
Progesterone and oestrogen are important regulators of the immune system and angiogenesis in 
several types of cancer as well as during pregnancy (72-74). Although both estrogen (65) and 
progesterone receptors (66) have been described in melanoma cells, the clinical significance for 
melanoma development and progression remains unclear. Meanwhile, the treatment of melanoma 
with Tamoxifen has not shown any benefit (67, 68), which suggests that once melanoma develops, 
progression might not be linked to estrogens.  
 
There are also changes to the immune system during gestation, namely a reduction in cellular 
immunity to prevent rejection of the fetus (75, 76) that may affect melanoma growth.  Indeed the 
physiological process of gestation has been likened to the pathologic progression of cancer 
including proliferation, invasion, and systemic tolerance (72, 77).  Whilst evidence exists for this 
paradigm in some animal studies, supportive data from human studies is lacking. For example, 
Mauti et al (57) demonstrated that mouse gestation is associated with decreased natural killer cell 
cytotoxicity in the presence of increased myeloid-derived suppressor cell population and that 
growth of metastases was enhanced.  
 
Current melanoma management guidelines in Europe, the US and Australia provide little advice 
regarding family planning for clinicians managing women diagnosed with melanoma during their 
reproductive years (42-44). To improve our understanding of whether the course of melanoma in a 
woman may be altered by a subsequent pregnancy we conducted a systematic review and meta-
analysis of the relevant literature published to date.  
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Methods 
Search strategy  
The systematic review and meta-analysis was conducted in accordance with the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines (78). We 
searched the Cochrane Database (1996-April 2013), MEDLINE (1950-April 2013), EMBASE 
(1966-April 2013), CINAHL (1982-April 2013), and PUBMED (1951-April 2013) using the MESH 
terms “Pregnancy”, “Prognosis”, and “Melanoma”. Selected articles’ reference lists were reviewed 
for additional relevant papers. The search was limited to studies published in the English language. 
 
Selection of Studies and Extraction of Data 
Studies were identified as eligible for review if they investigated melanoma outcomes in women 
who experienced a pregnancy after diagnosis and treatment of melanoma, if they included a 
comparison group and outcome measures reported were risk of melanoma death and/or disease-free 
survival. Eligible study designs were population, clinical and hospital-based cohort studies of 
females of childbearing age with confirmed diagnoses of primary cutaneous melanomas. Eligible 
comparison groups included nulliparous women, or women who remained non-pregnant following 
their melanoma diagnosis. The period of time between a melanoma diagnosis and subsequent 
pregnancy was noted if documented. Studies that reported a hazard ratio with a 95% confidence 
interval (CI) were included in the meta-analysis and findings of the remaining studies were 
summarized narratively.  
 
Data synthesis 
Data were extracted by two independent reviewers (LB, LK) using a customised data extraction 
form. Information extracted included: year of publication, geographic location, study design and 
definition of pregnancy, melanoma characteristics (disease stage and histological type), patient 
characteristics (age at diagnosis, time between melanoma diagnosis and pregnancy), duration of 
follow-up, summary effect estimates (including crude and adjusted odds ratios and hazard ratios 
with 95% CIs), study outcomes (survival rates, disease-free intervals), matching of the patient 
groups, and details on adjustment for confounding variables. Design weaknesses and potential 
sources of bias were noted. If the patient groups were not matched, we recorded the demographic 
and clinical characteristics of each group for comparison.  
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Statistical analysis 
Individual study estimates were pooled using the weighted average method, where the weight of 
each study is inversely proportional to the study variance. We conducted a random effects meta-
analysis (49) in the presence of statistically significant heterogeneity, assessed using the Q statistic 
(50) (significance level at P<0·05), with inconsistencies quantified using the I2 statistic (51). 
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Results 
Our search strategy yielded 304 articles of which 136 were duplicates (Figure 1). The titles and 
abstracts were then examined for eligibility, and 163 articles were excluded. We identified 5 reports 
(22, 29, 39, 41, 45) that met the inclusion criteria for systematic review (Figure 1). Three studies 
were retrospective clinical cohorts (29, 39, 45) and two studies were population-based cohorts (22, 
41) (Table 1) with the number of patients with melanomas diagnosed prior to a pregnancy and 
followed up ranging from 12 to 966 across the studies.  One study (39) that considered patients who 
had melanoma diagnosed between pregnancies as their control group, was eligible for inclusion in 
the systematic review because they also compared the outcome for a subgroup of patients who 
remained non-pregnant after their melanoma diagnosis. We re-calculated their effect estimates 
using the patient group “melanoma after all pregnancies” as the reference category. 
 
Patients who had a pregnancy after their melanoma diagnoses had a lower mean age at diagnosis 
(26-27.3years) than those who did not have further pregnancies after their melanoma diagnosis 
(33.1-40 years) (Table 1).  Four studies (29, 39, 41, 45) included women with diagnoses of localised 
melanomas only and one study (22) included all stages of melanoma and adjusted for stage in the 
analysis.  
 
Melanoma Survival  
Five studies assessed the risk of melanoma death in women who had a pregnancy following their 
melanoma diagnosis with mean or median follow-up ranging from 5 to 20 years (22, 29, 39, 41, 
45). All 5 studies reported no significant difference in melanoma survival rates in women who had a 
subsequent pregnancy compared to women with melanoma that did not or were nulliparous (Table 
2). Only two studies (29, 45) reported the time period between melanoma diagnosis and subsequent 
pregnancy whereas a third study (41) considered pregnancy status after melanoma diagnosis as a 
time-dependent variable in the multivariate analysis.  
 
Three studies (22, 39, 41) reported quantitative estimates for melanoma survival rates after 11 to 20 
years, adjusted for patient age (and one for melanoma stage (22)), and these were included in the 
meta-analysis. None of these 3 had specified the period of time between melanoma diagnosis and 
subsequent pregnancy. The pooled hazard ratio for risk of melanoma death in relation to treated 
melanomas that were followed by a pregnancy was 0.81 (95% CI 0.60-1.09). There was no 
evidence of heterogeneity (p=0.284) or publication bias (Begg p=1.0; Egger p=0.8).  
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Melanoma recurrence  
Two studies assessed recurrence rates of localised melanoma in women who had a subsequent 
pregnancy (29, 45). The pregnancy occurred either within 5 years of the melanoma diagnosis (29) 
or an average of 40 months after the diagnosis (45). Both studies reported no difference in 
melanoma recurrence in women who were pregnant following their melanoma diagnosis compared 
to women who remained non-pregnant after their melanoma diagnosis (table 2) after 4-5 years of 
follow-up. As neither study quantified the risk of melanoma recurrence, meta-analysis could not be 
performed.   
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Discussion 
To evaluate the potential influence of a subsequent pregnancy on the prognosis of a previously 
diagnosed melanoma we conducted a systematic review of the literature. Meta-analysis of 
quantitative data available from 3 of the 5 relevant studies demonstrated no significant effect of 
subsequent pregnancy on the risk of melanoma death with adjustment for patient age (and 
melanoma stage for patients with melanoma metastasis at diagnosis). This was supported by 
findings of the other 2 not included in the meta-analysis. Quantitative data were not available to 
evaluate the influence of a subsequent pregnancy on the risk of recurrence of a previously 
diagnosed melanoma but findings from the 2 relevant studies suggested that recurrence of 
melanoma was not increased by a subsequent pregnancy.  
 
This study was conducted with the intention of providing the best available evidence to clinicians to 
help them advise women with melanoma about possible risks of childbearing in the short- to 
medium-term. Current melanoma guidelines (42-44) are inconsistent in their advice to female 
melanoma survivors regarding future pregnancies. Specifically, neither the 2011 American 
Academy of Dermatology melanoma guidelines (42) nor the 2012 European Dermatology Forum 
guidelines for melanoma management (43) have any recommendations regarding timing of 
subsequent pregnancies, while current clinical practice guidelines for the management of melanoma 
in Australia and New Zealand (published 2008) (44) recommend that women avoid pregnancy for 2 
to 5 years following diagnosis of melanoma. The results of our systematic review show no firm 
grounds for a woman to delay pregnancy after the successful treatment of melanoma. However, due 
to of the small number of identified studies and the wide confidence interval for the hazards ratio on 
meta-analysis, we suggest that these patients be approached with some precaution, though 
counselling will be largely driven by known prognostic factors such as thickness and ulceration of 
the primary tumour (11).  
 
Besides the poor statistical power of the included studies, other methodological limitations were 
lack of detailed histological information on women’s primary melanomas, and variable follow-up 
periods. Studies not eligible for inclusion in the meta-analysis had shorter follow-up periods (5 to 
10 years) compared with those included in the meta-analysis (11 to 20 years). Another major 
limitation of the studies included in the meta-analysis was the lack of information regarding the 
timing of a pregnancy following the melanoma diagnosis. This bears directly on a major concern to 
be addressed when providing family planning advice for a melanoma survivor, namely the period of 
time when recurrence is most likely, which in turn varies with the clinical stage (79, 80). The 
systematic review as a whole was limited by the small number of studies that have evaluated this 
! 62 
important clinical question, and this was particularly true regarding melanoma recurrence as the 
outcome, where we identified a dearth of relevant studies and a complete absence of quantitative 
evidence. 
 
Conclusion 
The findings of our systematic review and meta-analysis suggest there is no significant influence of 
a subsequent pregnancy on the outcome of a previous melanoma. However, in view of the wide 
confidence interval around the pooled estimate for risk of melanoma death, some ill effect of a 
subsequent pregnancy cannot yet be ruled out. 
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Figure 1: Study selection 
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Figure 2: Risk of melanoma death for melanomas followed by pregnancy 
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Table 1: Study characteristics 
Reference Study design Population 
source 
Time 
period 
Mean/ 
median 
Follow-
up 
period 
N 
cases 
Primary group  
(N cases) 
Patient age  
Comparison group/s 
(N cases) 
Patient age  
Melanoma 
stages 
included 
Reintgen et 
al 1985 USA 
(29) 
Retrospective 
clinic-based 
cohort study 
Duke University 
Comprehensive 
Cancer Center. 
1972-
1983 
5 years 631 Pregnant within 5 years 
of melanoma (46) 
Mean age: 26.9yrs 
Non-pregnant within 5 years 
of melanoma (585) 
Mean age: 33.1yrs 
Stage 1 
 
McManamny 
et al 1989 
UK(45) 
Retrospective 
clinic-based 
cohort study 
Melanoma 
register and 
follow-up 
questionnaire 
1967-not 
specified 
2mths-
20yrs 
160 Melanoma before 
pregnancy (23) 
Mean age: 27.3yrs 
Non pregnant after 
melanoma (137) 
Mean age not specified 
Stage 1 
Mackie et al 
1991 UK 
(39) 
Retrospective 
clinic-based 
cohort study 
WHO 
melanoma 
program study 
Not 
specified 
20 
years  
297 Melanoma before 
pregnancy (86) 
Age groups 
<22yrs: 23 
23-26yrs: 32 
27-30yrs: 21 
31-40yrs: 9 
>41yrs: 0 
Non pregnant after 
melanoma diagnosis (143) 
Age groups 
<22yrs: 7 
23-26yrs: 36 
27-30yrs: 35 
31-40yrs: 57 
>41yrs: 8 
 
Stage 1 
Lens et al 
2004 UK 
(41) 
Retrospective 
population 
based cohort 
study 
Swedish 
National and 
Regional 
Registries:  
Jan 01 
1958- 
Dec 31 
1999 
Mean 
12.9 
years 
5535 Melanoma before 
pregnancy (966) 
Mean age: 26.5yrs 
Melanoma after all 
pregnancies (4569) 
Mean age: 36.6yrs 
 
Stage 1 
 
Stensheim et 
al 2009 
Norway (22) 
Retrospective 
Population 
based cohort 
study 
Data linkage 
between the 
Cancer registry 
and the medical 
birth registry of 
Norway  
1967-
2002 
Median 
11.4-
15.4 
years 
4746 Melanoma before 
pregnancy (797) 
Median age: 26 yrs 
 
Nulliparous/ melanoma after 
pregnancy (3949) 
Median age: 40 yrs 
 
All stages 
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Table 2: Study results 
Reference Statistical 
analysis 
Risk of melanoma death 
(patient group, N cases) 
Risk of recurrence 
(patient group, N cases) 
Period of time between 
melanoma diagnosis 
and pregnancy 
Adjustment for 
confounding 
factors 
Reintgen et 
al 1985 USA 
(29) 
Multivariate 
regression 
analysis 
Melanoma death rate 
Pregnant within 5 years of 
melanoma (46) 20%, p=0.50 
 
Non-pregnant within 5 years of 
melanoma (585) (control group) 
17% 
Pregnant within 5 years of 
melanoma (46) 44%, p=0.31 
 
Non-pregnant within 5 years of 
melanoma (585) (control 
group) 30% 
 
Within 5 years Clark's Level, 
ulceration, and 
tumor thickness. 
 
McManamny 
et al 1989 
UK (45) 
Mantel cox 
statistic  
Melanoma death rate 
Melanoma before pregnancy (23) 
13%, p=0.21 
 
Non pregnant after melanoma (137) 
(reference group) 21% 
 
Melanoma before pregnancy 
(23) 22% p=0.38 
- 100% within 4 years 
 
Non pregnant after melanoma 
(137) (reference group) 27% 
- 84% within 4 years 
Average: 40 months 
 
None  
No difference 
found between 
anatomical site 
and thickness 
between groups 
Mackie et al 
1991 UK 
(39) 
Hazard ratio Melanoma before pregnancy (86)  
HR 1.70 (CI 0.45-6.40) 
 
Melanoma after pregnancy (143) 
(reference group) HR 1.0 
NA Not specified Site and tumour 
thickness 
Lens et al 
2004 UK 
(41) 
Hazard ratio Melanoma before pregnancy (966) 
HR 0.58 (CI 0.32-1.05), p=0.07 
 
Melanoma after all pregnancies 
(4569) (reference group) HR 1.0 
NA Not specified Breslow thickness, 
tumor site, Clark’s 
level, and age.  
Stensheim et 
al 2009 
Norway (22) 
Hazard ratio Melanoma before pregnancy (797) 
HR 0.86 (CI 0.60-1.22) 
 
Nulliparous or melanoma after 
pregnancy (3949) (reference group)  
HR 1.0 
NA Not specified Age at diagnosis, 
stage, and 
diagnostic periods 
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General Discussion 
Providing family planning advice for a melanoma survivor can be challenging, as the current 
international melanoma guidelines (42-44) are inconsistent in their provision of advice. Neither the 
American Academy of Dermatology melanoma guidelines (42) nor the European Dermatology 
Forum guidelines for melanoma management (43) have any recommendations regarding timing of 
subsequent pregnancies. The Australia and New Zealand guidelines (44) recommend that women 
avoid pregnancy for 2 to 5 years following diagnosis of a high-risk melanoma. However, no 
guidelines are provided for localized melanomas. This article includes mostly localized melanomas 
which may assist in providing advice for this subset of women. 
 
This study found that melanoma survivors with localised melanoma in remission may become 
pregnant without undergoing additional risks. However, evidence was scarce with three studies 
eligible for meta-analysis. Combined with the wide confidence interval for the pooled estimate I 
propose that this group of patients be approached cautiously and on an individual ‘case-by-case’ 
basis when providing advice for future childbearing plans. The meta-analysis findings include 
predominantly localised melanomas therefore it is unclear if a subsequent pregnancy has an impact 
on a previously diagnosed melanoma that is advanced stage. Given the increased risk of a second 
primary melanoma in this population (81, 82), I also suggest a thorough skin examination of this 
category of patients prior to a planned pregnancy.  
  
For example, a woman who has had a successfully treated stage I melanoma may become pregnant 
without an affect on her risk of death from that melanoma. In comparison, a woman who is in 
remission after a successfully treated stage III will need to be approached with caution when 
providing childbearing advice. When providing family planning advice to this patient known 
prognostic factors will need to be taken into account.  
 
Another concern is the period of time when recurrence is most likely.  Recurrence rates depend on 
the thickness of the melanoma but are also dependent on the time from diagnosis. Thin melanomas 
<1.5mm have a recurrence rate of approximately 6% for the first 5 years, however, this decreases to 
less than 1% after this point. In comparison melanomas of >1.5mm have a greater risk of recurrence 
in the first year following a diagnosis. This then decreases to below 2% after the first 5 years (83-
85).  Across all melanoma stages approximately 80% of recurrences will occur in the first 3 years 
(83, 86, 87). If recurrence develops during a pregnancy it can have implications not only for the 
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mother but also for the fetus. This is more applicable in the approach to the woman with advanced 
stage melanoma compared to the patient with a successfully treated localised melanoma. 
 
The rare event of a woman with a previous pregnancy-associated melanoma who then has a 
subsequent pregnancy was unable to be captured based on the registry data presented by the studies 
included in this article. Given the findings of increased mortality in pregnancy-associated 
melanomas in the previous chapter this is an important clinical consideration. Population-based 
studies would be required to assess if a subsequent pregnancy may worsen the natural course of the 
previous pregnancy-associated melanoma.  
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CHAPTER 4 
The influence of parity on melanoma prognosis  
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Introduction 
Melanoma outcome differs substantially depending on the sex of the patient. This phenomenon was 
first noted in 1967 by Clark et al (88) who reported more aggressive behaviour of melanomas 
occurring in males in comparison to females. Since then females have been consistently reported to 
have improved survival rates compared to males after adjustment for known prognostic factors, 
such as melanoma thickness and patient age (13, 15, 89). An underlying biologic basis has been 
previously suggested (89-91). Among reproductive factors, the influence of parity on melanoma 
prognosis has rarely been addressed yet may be relevant given the lack of any clear explanation for 
the improved survival of females compared to males (13, 15). A recent study further showed that 
nulliparity was associated with increased risk for disease-specific death when adjusted for age, 
localisation, stage, and Breslows thickness (34). Females with at least one pregnancy prior to the 
diagnosis of melanoma had improved survival rates compared to nulliparous females.  
 
I here aimed to compare survival rates between nulliparous and parous females diagnosed with 
melanoma in a representative cohort of Queensland melanoma patients with long follow-up. I 
further aimed to compare survival rates between males and females according to the females’ 
parity. It was assumed that if parity is responsible for the improved survival in the female 
population, nulliparous women should have a similar melanoma survival outcome as males. 
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Methods   
A population based case-control study of melanoma was conducted by Professor Green based on a 
random sample of 243 patients drawn from all 871 Queensland residents. Patients were included if 
they were aged between 15 and 81 years with a primary melanoma histologically diagnosed 
between 1st July 1979-30th June 1980. Matched controls were obtained from the electoral roll. 232 
of the cases were successfully contacted and interviewed (92) and these  patients formed the cohort 
assessed for melanoma mortality in the present study. Data collected at personal interview included 
females’ reproductive history, including parity (but not history of pregnancies). Pathology records 
were examined for age at diagnosis and information specific to their diagnosed melanoma including 
anatomical site, histological classification, tumour thickness, and Clarks level. 
 
From this historical cohort, patient data were transferred to the Queensland Cancer Council (QCR) 
for retrieval of survival status for each patient at the time of the present study. The QCR collects 
mortality data on all cancer patients within Queensland (93). The results regarding melanoma 
mortality were de-identified and transferred to QIMR Berghofer Medical Research Institute for 
analysis according to females’ parity prior to melanoma diagnosis.  
 
Analysis 
Patients were categorised into three subgroups for comparison: parous females, nulliparous females 
and males. I assessed the relationship of parity and melanoma-specific survival within females and 
between the sexes at 30 years follow-up from their melanoma diagnosis. Those patients alive at 30th 
June 2012 were censored at this point. Analysis of selected melanoma characteristics, patient 
characteristics, and melanoma-specific survival estimates (in situ melanomas excluded) were 
conducted using SPSS Statistics (94). Comparisons between the baseline melanoma characteristics 
were calculated using Chi square test (significance level at p<0.05). Ten year Kaplan-Meier 
melanoma cause-specific survival estimates were generated.  
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Results  
Patient characteristics: 
There were 114 females (49%) in the study group, of whom 16 (14%) were nulliparous, 98 (86%) 
were parous including 21 multi-parous women (5 or more pregnancies) at diagnosis of melanoma.  
There were 118 men (51%) included. The mean age at diagnosis was 41.0 years for the non-parous 
females, 47.5 years for the parous females, and 53.2 years for the 118 males. 
 
Anatomical site, Clarks level, and histological class were significantly associated with parity status 
(table 1). Parous females were more likely to have melanomas diagnosed on their limbs (63%) 
whereas nulliparous females and males were more likely to have truncal melanomas (31% and 46% 
respectively) (table 1). Parous and nulliparous females were more likely to be diagnosed with level 
1 melanomas (70% and 69% respectively) compared with males who were more likely to be 
diagnosed with level 3 melanomas (25%). Nulliparous females and males were also more likely to 
be diagnosed with nodular melanomas (19% and 22% respectively) compared to females (8%). The 
majority of patients were diagnosed with melanomas <1.5mm (90%). There was no difference 
between the subgroups for tumour thickness (p=0.895). 
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Table 1: Melanoma characteristics of 232 patients 
Patient subgroups (%) Total p-value  
Parous 
female 
(N=98) 
Nulliparous 
female 
(N=16) 
Male 
(N=118) 
  
Head and neck 22 (22%) 4 (25%) 28 (24%) 54 
Trunk 15 (15%) 5 (31%) 54 (46%) 74 
Upper limb 24 (25%) 4 (25%) 22 (18%) 50 
Site 
Lower limb 37 (38%) 3 (19%) 14 (12%) 54 
p<0.001+ 
0-0.75 34 (35%) 6 (37%) 38 (32%) 78 
0.76-1.50 58 (59%) 10 (63%) 62 (53%) 130 
1.51-4.0 0 (0%) 0 (0%) 1 (1%) 1 
Thickness 
(mm) 
Unknown 6 (6%) 0 (0%) 17 (14%) 23 
p=0.895+ 
Level 1 69 (70%) 11 (69%) 61 (52%) 141 
Level 2 19 (19%) 3 (19%) 21 (18%) 43 
Level 3 10 (11%) 2 (12%) 30 (25%) 42 
Level 4 0 (0%) 0 (0%) 3 (3%) 3 
Indeterminate 0 (0%) 0 (0%) 2 (1%) 2 
Clarks level 
Unknown 0 (0%) 0 (0%) 1 (1%) 1 
p=0.007+ 
SSM 68 (69%) 11 (69%) 62 (53%) 141 
LMM 21 (22%) 2 (12%) 26 (22%) 49 
Nodular 
melanoma 
6 (6%) 3 (19%) 26 (22%) 35 
Histological 
class 
Indeterminate 3 (3%) 0 (0%) 4 (3%) 7 
p=0.044+ 
 
SSM superficial spreading melanoma 
LMM lentigo maligna melanoma 
+ Calculated using Chi square test 
 
Survival analysis 
All groups combined had a mean follow-up period of 32 years. Ninety patients (39%) were known 
to have died (table 2), of whom 21 patients (23%) died from melanoma.  Of these 21 patients seven 
(7%) were parous females, one (6%) was a nulliparous female, and 13 (11%) were males. Mean 
time from diagnosis to death was 19.4 (SE 1.46) years in the parous females and 17.2 (SE 5.77) 
years in the nulliparous females. In comparison, the males had a mean time to death of 13.1 (SE 
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1.34) years. Given the lack of deaths among nulliparous females any difference in survival between 
parous and nulliparous groups could not be evaluated. Unadjusted Kaplan Meier survival analysis 
(in situ melanomas excluded) demonstrated a consistently increased time from diagnosis to death in 
the parous females, in comparison to the males (figure 1).  Further assessment of possible survival 
differences adjusted for confounding factors was not feasible due to insufficient numbers of 
melanoma deaths ascertained in this study cohort. 
 
Table 2: Cause of death 
Patient subgroups  
Parous female 
(N=98) 
Non-parous 
female 
(N=16) 
Male 
(N=118) 
Total 
Melanoma 7 1 13 21 
Other cancer 10 0 12 22 
Non-cancer death 18 2 27 47 
All cause 35 3 52 90 
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Figure 1: Kaplan Meier Survival curve for males, parous females and non-parous females 
 
 
“ttdeath” number of years from diagnosis to death 
Censored at 30th June 2012 
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Discussion 
This was an exploratory study, and while the unadjusted results suggest that parity does not 
influence melanoma survival, further analysis was not possible due to the small numbers of 
nulliparous females (N=16) in the study cohort and the limited number of melanoma deaths (N=21) 
that were ascertained. Thus while males did demonstrate shorter survival periods between diagnosis 
and death compared to parous females, this could be explained entirely by the poorer prognosis of 
the melanomas among males at baseline, since they were more likely to be diagnosed on the trunk, 
have nodular melanomas, have a higher Clarks level, and be older at time of diagnosis (95, 96). 
  
It has previously been suggested that a prior pregnancy has a protective influence on melanoma 
prognosis with reduced risk of death and distant metastases (34, 97).  The number of previous 
pregnancies, or parity, has also been shown to affect the degree of survival benefit observed in 
females. Multi-parity (more than 3 pregnancies) has been demonstrated to have a reduced risk of 
melanoma development and progression (34, 98). This benefit may be due to fetal maternal 
chimerism, which is the natural transfer of fetal cells to maternal circulation (99). These fetal cells 
are semi-allogenic thus may react against neoplastic tissues (100). However, the immunological 
consequences of this are still being investigated. 
 
A limitation of this study includes the small sample size. As above, despite having a very long 
follow-up period, our relatively small cohort did not allow for statistical analysis of differences in 
survival rates. The major limitations however were in regards to matching the cohort of 232 cases 
against QCR files at 30-year follow-up. For accurate data matching between the original data set 
(1979-1980), pathology records, and the QCR all patient information needed to be correctly 
entered. Patients’ full names, dates of births, and addresses at time of diagnosis were required for 
matching. A simple spelling error would result in the patient not being able to be matched to 
ascertain survival. Additionally, if a patient changed their name, for example by marriage, or by 
moving interstate, I would also not be able to collect information regarding their survival. This 
meant that the mortality rates for this cohort were likely to be underestimated, as would be the 
deaths due to melanoma.  
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Conclusion 
The survival advantage of females over males for melanoma has not been explained to date in the 
literature. An underlying biologic mechanism such as parity and pregnancy has been proposed as an 
explanation. Our unadjusted results suggest that males have reduced survival however the influence 
of parity could not be fully investigated due to small sample size. This question needs to be 
addressed in a long-term follow-up study comparing melanoma outcomes between parous females, 
nulliparous females, and males with complete data on survival. 
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CHAPTER 5 
Melanoma survival is superior in females across all 
tumour stages but is influenced by age  
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In the previous chapter the small sample size and likely underestimation of mortality rates did not 
allow for evaluation of the effect of parity on melanoma outcome. Underlying biological factors, 
such as pregnancy, parity, and sex hormones, may still contribute to the female survival advantage 
in melanoma. Parity, sex hormones, and pregnancy vary in women of specific age groups. I 
compared melanoma survival between men and women across age categories according to stage of 
female reproductive life thus reflecting different hormonal status in women.  This aimed to 
indirectly evaluate the influence of parity, sex hormones, and pregnancy on melanoma outcome. 
 
 
!!! 80 
Title page 
Melanoma survival is superior in females across all tumour stages but is influenced by age  
 
Kiarash Khosrotehrani*, Paramita Dasgupta*, Lisa Byrom, Danny R Youlden, Peter D Baade, Adele 
C Green 
* Contributed equally as first authors 
 
Corresponding author: 
Name: Kiarash Khosrotehrani 
Degrees: MD, PhD, FACD 
Affiliations: The University of Queensland, UQ Centre for Clinical Research, Experimental 
Dermatology Group, Brisbane, QLD, Australia. The University of Queensland, UQ Diamantina 
Institute, Translational Research Institute, Woolloongabba, QLD, Australia 
Address: The University of Queensland Centre for Clinical Research, Royal Brisbane Hospital 
Building 71/918, Herston, QLD 4029, Australia 
Tel: +61733466077, Fax:+61733465598 
Email: k.khosrotehrani@uq.edu.au 
 
Author 2: 
Name: Paramita Dasgupta 
Affiliations: Cancer Council Queensland, Brisbane, QLD, Australia 
Address: Cancer Council Queensland, PO Box 201, Spring Hill QLD Australian 4004 
 
Author 3: 
Name: Lisa Byrom 
Affiliations: The University of Queensland, UQ Centre for Clinical Research, Experimental 
Dermatology Group, Brisbane, QLD, Australia. The University of Queensland, UQ Diamantina 
Institute, Translational Research Institute, Woolloongabba, QLD, Australia 
Address: The University of Queensland Centre for Clinical Research, Royal Brisbane Hospital 
Building 71/918, Herston, QLD 4029, Australia 
 
Author 4: 
Name: Danny R Youlden 
Affiliations: Cancer Council Queensland, Brisbane, QLD Australia 
Address: Cancer Council Queensland, PO Box 201, Spring Hill QLD Australian 4004 
!!! 81 
 
Author 5: 
Name: Peter D Baade 
Affiliations: Cancer Council Queensland, Brisbane, QLD, Australia. School of Public Health and 
Social Work, Queensland University of Technology, Brisbane, QLD, Australia 
Address: Cancer Council Queensland, PO Box 201, Spring Hill QLD Australian 4004 
 
Author 6: 
Name: Adele C Green,  
Affiliations: QIMRBerghofer Medical Research Institute, QLD, Australia. CRUK Manchester 
Institute and Institute of Inflammation and Repair, University of Manchester, Manchester Academic 
Health Sciences Centre, Manchester, UK 
Address: QIMR Berghofer Medical Research Institute, Locked Bag 2000, Royal Brisbane Hospital, 
QLD, Australia 4029 
 
Accepted by the Archives of Dermatological Research  
Archives of Dermatological Research is a highly rated international journal that publishes original 
contributions in the field of experimental dermatology, including papers on biochemistry, 
morphology and immunology of the skin. The journal is among the few not related to 
dermatological associations or belonging to respective societies, which guarantees complete 
independence. This English-language journal also offers a platform for review articles in areas of 
interest for dermatologists and for publication of innovative clinical trials. 
!!! 82 
 
Abstract  
Background 
Among patients with invasive melanoma, females are known to have higher survival than males 
globally. However this survival advantage has not been explored in thin melanomas, the most 
common form of the disease. In addition, it is unclear if this advantage is true across all age groups. 
 
Objective 
We aimed to compare melanoma survival between males and females by clinical stage and within 
age groups.  
 
Methods 
Melanomas from 1995 to 2008 were extracted from the Queensland Cancer Registry and the 
Surveillance, Epidemiology, and End Results (SEER) Program and melanoma-specific deaths were 
ascertained up to 2011. Flexible parametric survival models compared survival between groups.  
 
Results 
The Queensland cohort of 28,979 patients experienced 1,712 melanoma deaths and the SEER 
cohort of 57,402 patients included 6,929 melanoma deaths. Survival rates were in favour of females 
across nearly all tumour stages, including thin invasive tumours in both cohorts after adjusting for 
demographic and clinical factors (Odds Ratio (OR) death female: male for stage I melanoma = 0.64 
in Queensland; and OR=0.79 in the US, both P<0.001). The sex influence on survival interacted 
with age categories. In particular, the survival advantage was inconsistent in females with stage I 
melanoma aged under 60. 
 
Conclusion  
Females with melanoma have a survival advantage over males including in stage I melanomas. 
However, this advantage is dependent on age at diagnosis, suggesting an underlying biological 
mechanism influenced by age that exists from the very early stages of the disease. 
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Introduction 
The role of fundamental host factors such as sex whose influence on melanoma survival has been 
known for decades remains to be understood (88, 101). Females have a clear melanoma-specific 
survival advantage over men (13). This advantage has also been seen in patients with advanced 
metastatic melanoma classified as stages III or IV suggesting sex-specific biological rather than 
behavioural differences explain the female survival benefit (102). That is, the observed differences 
in survival between men and women seem unrelated to possible delays for males in diagnosis or 
management or to other differences in melanomas between males and females such as tumour site. 
Although most patients are diagnosed with thin melanomas, the female survival benefit has not 
been explored to the same extent in this population to date (13, 15, 89). In particular, previous 
studies that focused on stage I and II melanomas report inconsistent female survival advantage for 
thinner melanomas (14, 15, 103). Also it is unclear if this survival advantage persists across all age 
groups after adjustment for stage of disease at diagnosis. This is of importance as pregnancy and 
reproductive hormones significantly change during women’s lifespan. 
 
In the present study, we aimed to compare melanoma survival between males and females across all 
stages of melanoma diagnoses. We used data from two large population cohorts of melanoma from 
the Australian state of Queensland and the United States to specifically quantify the influence of sex 
on melanoma survival including thin localised melanomas across different age groups. 
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Patients and methods 
Data extraction: Australian cohort 
All histologically verified incident cases of first primary invasive melanomas (C44, M872-879) 
diagnosed in Queensland from 1995-2008 among people aged 15-89 years were extracted from the 
Queensland Cancer Registry (93).  In addition to patients’ sex and age at diagnosis, tumour-related 
variables, namely body site, thickness, level of invasion, ulceration, histologic type, nodal spread 
and distant metastasis were manually extracted from pathology reports held by the Registry. 
Tumour thickness, ulceration, nodal spread and metastasis were categorized according to the 
criteria used for the American Joint Committee on Cancer (AJCC-seventh edition) classification for 
melanoma (11). 
 
The Queensland Cancer Registry matched incident data against the Queensland Registrar of Births, 
Deaths and Marriages and the National Death Index to ascertain all deaths that occurred within the 
cohort up to 31st December 2010. All available information from death certificates, autopsy reports, 
health care facility notifications and pathology reports were used to code cause of death (93). This 
study was approved by the University of Queensland Human Research Ethics Committee. 
 
Data extraction: USA cohort 
Incident cases from the United States were extracted from the Surveillance, Epidemiology, and End 
Results SEER-9 database (SEER) (104). Similar inclusion criteria were used to those described 
above, involving patients aged 15-89 years at the time of diagnosis of a histologically confirmed 
first and only primary invasive melanoma. Cases in this cohort also were diagnosed from 1995-
2008 and followed-up until December 31, 2010.  
 
Variables extracted included year and month of diagnosis, sex, age, as well as tumour-related 
variables as detailed above. For survival analysis the cause of death and survival time were 
extracted. All variables were coded according to the documentation (104) for the SEER incidence 
data and grouped as for the Queensland cohort.  
 
Patient groups 
Females and males were divided into three broad age groups based on age at diagnosis:  15-45 
years, 46-59 years and ≥ 60 years to match previous studies on this subject (102). Patients aged 
under 15 or over 89 years at diagnosis were not considered given the peculiar disease evolution in 
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children and since death certificates are less precise in very old patients (105, 106). Survival 
outcomes for females were compared with males in the same age group.  
 
Statistical analysis 
Due to missing data in the registries for body site, thickness, level of invasion, ulceration, and nodal 
spread and, for USA only, metastasis, a complete case analysis would have excluded significant 
proportions of each cohort. To reduce the risk of bias from missing data, multiple imputations with 
chained equations (107) were used to estimate a set of plausible values for these variables for each 
cohort separately. The imputation strategy has been described previously (108). Briefly 30 data sets 
with no missing values were imputed based on multivariable imputation models that included all 
variables (except stage), as well as the Kaplan-Meier estimate of the survival curve, vital status (i.e. 
whether patients were alive or dead at study end), and the interaction between survival time and 
vital status. The imputed values of thickness, ulceration, metastasis and nodal spread were 
combined to obtain estimates of the stage where it was missing for each multiple imputed dataset 
during the modeling process.  
 
Melanoma-specific survival estimates were calculated. Deaths from non-melanoma causes before 
31st December 2010 were censored at date of death and those alive at 31st December 2010 were also 
censored. Cases for both cohorts were excluded if they had multiple melanomas, were identified by 
death certificate only, nursing homes (SEER data only) or autopsy, or survived for less than 1 day 
after diagnosis. 
 
Median follow-up times were determined using the reverse Kaplan-Meier method (109). Ten year 
Kaplan-Meier melanoma cause-specific survival estimates were generated and estimates compared 
between males and females with the log rank test. The stratified log-rank test was used to compare 
the survival of males and females across other patient characteristics (110). 
 
Flexible parametric survival models 
Flexible parametric Royston Parmar (RP) survival models (111) were used to analyse melanoma-
specific survival over the entire time period (i.e.16 years) for both cohorts. We restricted our choice 
of scales to proportional hazards (hazards ratios) and proportional odds (odds ratios) models to 
facilitate interpretation of the covariate effects (111).  For our data, the best fits for both cohorts 
were provided by the odds scale, and the baseline log odds of an event were modeled as a restricted 
cubic spline with 2 knots (3 degrees of freedom).  
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The current models build upon a previously published model (108) with the inclusion of sex as a 
variable. Age at diagnosis and thickness were modeled as continuous variables. Covariate selection 
and transformation of continuous variables were undertaken using a multivariate fractional 
polynomial (MFP) process (112) designed for multiple imputed data (111). The final adjusted 
models for both cohorts included the variables sex, age, body site and thickness of the primary 
tumour, ulceration, nodal spread, and metastasis. Level of invasion and histology were not retained 
in the final models due to low discriminatory power. 
 
The crude (unadjusted) and adjusted odds ratios (ORs) were generated for female compared with 
male melanoma-specific mortality with 95% confidence intervals (CIs). We also calculated sex-
specific ORs stratified separately by age categories and disease stage, along with the combination of 
both variables. Finally, evidence for the interaction between sex and age groups was assessed by 
including appropriate second-order terms in the fully adjusted models.  
 
All analyses were carried out using Stata/SE version 13.1 (StataCorp, TX, USA). Flexible 
parametric survival models were fitted with stpm2 (113). The mim (114) command was used for 
estimating survival models with interaction terms over the multiple imputed data sets. Pearson chi-
squared tests were used to compare category-specific distributions of cases. 
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Results 
Study populations 
The Queensland cohort consisted of 28,979 patients (males 57%) with a median follow-up of 7.2 
years (interquantile range (IQR)=4.2-10.9 years). There were 57,402 patients in the United States 
cohort (54% males) with a median follow-up of 7.3 years (IQR=4.3-11.0 years). The majority of 
patients (23,156 or 80% in the Queensland cohort and 31,934 or 56% in the US cohort) were 
diagnosed at stage I melanoma. In both cohorts, males were more likely (P<0.001) to be diagnosed 
at an older age and have thicker or ulcerated melanomas (P<0.001) and were less likely to develop 
melanomas on their lower or upper limbs (P<0.001) than females.  
 
Sex- and melanoma-specific survival 
There were 1,712 (6%) melanoma-specific deaths in Queensland and 6,929 (12%) in the United 
States over the entire study period. The overall 10-year cause-specific survival rates were lower 
among males than females in both cohorts (P < 0.001, Table 1). In particular, the female survival 
benefit was seen for patients with melanomas thinner than 1mm across both cohorts: crude 10-year 
survival of patients with <1mm thickness melanoma in Queensland was 97.3% in males versus 
98.6% in females and in the US cohort, 96.1% in males versus 98.0% in females (Table 1). Both 
melanomas of the limbs and the trunk displayed a better survival in females. In patients with a trunk 
melanoma comprised predominantly of males, crude 10-year survival significantly favoured 
females (in Queensland, 91.7% in males versus 94.9 % in females; in the US cohort, 89.0% in 
males versus 93.1% in females).  
 
When considering all patients and after adjusting for all demographic and clinical factors, the 
significant female survival advantage remained (OR female:male = 0.73 (0.64-0.82) for Queensland 
and 0.75 (0.69-0.80) for the US cohort, P<0.001 for both) (Table 2).  
 
Influence of stage at diagnosis 
The survival advantage among females was apparent across virtually all AJCC tumour stages 
(Table 2). In particular, women with Stage I and Stage II (locally invasive) melanomas displayed 
better survival compared to men across both cohorts. For example, among patients with stage I 
disease, females had a significantly better survival over males after adjustment for other prognostic 
factors (OR death female:male = 0.64 (0.51-0.82) in Queensland and 0.79 (0.68-0.92) in the US, 
P<0.001 for both). For stages III/IV, females survived better than males in the US cohort (OR 
female:male = 0.78 (0.68-0.90), P<0.001) while in Queensland with a relatively small number of 
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cases (n=346) the female survival advantage did not reach significance (OR female: male = 0.70 
(0.44-1.10), P=0.120). 
  
Patient age groups  
When patients were stratified by age group, females consistently had significantly better survival 
than males after adjustment for other factors (Table 3), except for the 45-59 age group in 
Queensland who failed to display a significant survival advantage in women. There was significant 
evidence of interaction between sex and age group in both cohorts (P=0.035 in Queensland and 
P=0.007 in the US). 
 
When we examined survival of males and females within the three age groups by disease stage at 
diagnosis, only females in the oldest age group (>60 years) displayed a survival advantage over 
males across all stages. In particular among stage I melanomas, women aged 45-60 did not display 
any significant survival advantage in either cohort and the female benefit for those aged 15-45 was 
borderline in the US cohort and also absent in the Queensland cohort despite large numbers of 
cases. 
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Discussion 
The melanoma survival advantage in women has been extensively detailed in large European 
cohorts (13) and in pooling large clinical trials (15, 102). Additionally, females have previously 
been reported to have a reduced risk of lymph node and visceral metastases and retain their survival 
advantage over males after disease progression (13). These data from two population cohorts in 
Australia (Queensland) and the United States have now quantified the female advantage in larger 
populations permitting a more detailed analysis by stage of melanoma. Indeed the survival benefit 
in females with melanomas thinner than 2mm that we clearly describe here has not been 
demonstrated in some previous studies (15).  
 
Melanomas diagnosed in men and women often differ in a number of known prognostic factors 
such as measured thickness or site of the primary tumour. In both population cohorts we found that 
males were significantly more likely to have thick or ulcerated melanomas and more likely to be 
diagnosed on the trunk. In this study, adjustment for such factors indeed reduced the survival 
benefit observed in women but did not remove it. That the survival benefit in women remained 
generally evident across tumour stages suggests that the residual survival benefit observed in 
women after adjustment has a biological basis that is effective from the very early stages of the 
primary tumour invasion until the establishment and the progression of metastases. However, our 
large cohorts were composed mainly of men as the incidence of melanoma is higher in men than in 
women in both the USA (24.6 versus 15.8 per 100,000) and Australia (59.9 versus 38.9 per 
100,000) (115, 116). It would be of interest to study populations where the female incidence of 
melanoma is higher such as in Denmark or Netherlands (10) providing greater statistical power to 
assess females’ relative survival.  Finally, while both datasets were of high quality overall, the 
substantial missing data on stage of disease at diagnosis was a major limitation of the US data 
which we sought to overcome by multiple imputation. Also the Queensland dataset relying mostly 
on pathology reports is likely to have missed metastatic events that are not documented 
histologically potentially explaining some of the observed differences between the two cohorts. 
 
Beyond demonstrating the survival benefit of females across melanoma stages including the most 
common thin stage I melanomas, we further showed an interaction between the sex-related benefit 
in survival and age group whereby not all groups consistently displayed a female survival 
advantage. Part of this may be explained by the lack of power due to small number of cases in 
subgroup analyses, especially in the smaller Queensland cohort. However, even in the large 
category of stage I melanoma patients, only women older than 60 had a significant survival 
advantage over males in both cohorts. Further, in the US cohort with nearly 10,000 patients aged 
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46-59, females did not show any significant survival advantage over males. Therefore the female 
survival benefit in melanoma seems weaker in those younger than 45 at diagnosis and absent among 
those 46-59.  
 
Given the plausibility of biological factors accounting for the observed survival benefit in females, 
a potential role for female hormones has been proposed (88, 102). The patient age categories in fact 
generally reflect the different hormonal status in women. After puberty to the age of 45 there is 
cyclic activity of estrogen and progesterone that are present at high levels; the 45-60 group is 
representative of the peri-menopausal period that is mostly characterised by instability of the 
estrogen levels; and finally in the post-menopausal period the estrogen and progesterone levels are 
low (117, 118). However, there is heterogeneity among women within each age group mostly due 
to the variable use of oestroprogestative contraception or hormone replacement therapy (HRT) in 
peri-menopause. These treatments have not been consistently used among cohorts making it 
difficult to broadly conclude on the role of hormones through the study of age categories (119-123). 
Indeed the influence of estrogens on melanoma has been previously suggested (46, 65, 124, 125). 
Male androgens have also been demonstrated to stimulate melanoma cell proliferation and enhance 
tumour invasion (126-128) though the clinical implications of this remain unclear. Finally, 
pregnancy and the post partum period have also been reported to affect melanoma outcomes. In 
particular, parous women seem to have better melanoma survival compared to nulliparous controls 
(34, 100). This might further contribute to the increased difference observed between males and 
females after reproductive age. Using large registry-based cohorts, we did not have access to 
pregnancy history, use of contraceptives or HRT or hormonal levels. 
 
In conclusion, we here report the survival benefit observed in females compared with males with 
melanoma in two large population cohorts after stratification by age and stage and diagnosis 
combined with careful adjustment for a range of other key prognostic factors including primary 
tumour thickness and site. This benefit was observed across all stages including stage I melanomas, 
the most common presentation of the disease. However, the female survival benefit is influenced by 
age and it is not consistently demonstrated among those of younger or middle age (15 to 59 years 
old). Further studies need to directly explore the role of sex hormones in relation to melanoma 
survival. 
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Table 1: Ten-year melanoma-specific survival estimates by sex for Queensland and United States (SEER-9) based cohorts 1995-2008 (followed up to 
2010) 
 
 Queensland (N=28,979) United States (SEER-9) (N=57,402) 
 Males Females  Males Females  
Sub-group N(%) 10 year Survival (95%CI) N 
10 year Survival 
(95%CI) P
1 N 10 year Survival (95%CI) N 
10 year Survival 
(95%CI) P
1 
All patients 16,426 90.9 (90.3-91.4) 12,553 94.8 (94.3-95.2) <0.001 30,997 86.4 (85.9-86.9) 26,405 92.4 (92.0-92.7) <0.001 
           
Age groups2     <0.001     <0.001 
15-45 years 3,670 (22%) 
94.6 (93.7-95.4) 4,287 
(34%) 
96.7 (96.0-97.3)  7,021 
(23%) 
89.5 (88.6-90.2) 10,002 
(38%) 
95.8 (95.3-96.2)  
46-59 years 4,613 (28%) 
93.2 (92.3-93.4) 3,527 
(28%) 
95.7 (94.6-96.3)  9,698 
(31%) 
88.0 (87.2-88.7) 7,649 
(29%) 
93.3 (92.6-94.0)  
≥60 years 8,143 (50%) 
87.1 (86.1-88.1) 4,739 
(38%) 
92.3 (91.3-93.2)  14,278 
(46%) 
85.4 (82.7-84.2) 8,754 
(33%) 
87.2 (86.4-88.1)  
Ulceration     <0.001     <0.001 
No ulceration 
9,617 
(59%) 
94.3 (93.6-94.9) 7,670 
(61%) 
96.9 (96.4-97.4)  26,576 
(86%) 
89.7 (89.2-90.1) 23,334 
(88%) 
94.3 (94.0-94.7)  
Known ulceration 
1,703 
(10%) 
66.8 (63.9-69.6) 942 
(8%) 
77.2 (73.8-80.2)  2,567 
(8%) 
60.2 (57.7-62.7) 1,562 
(6%) 
70.4 (67.2-73.3)  
Unknown3 
5,106 
(31%) 
92.0 (91.1-92.8) 3,941 
(31%) 
94.7 (93.9-95.5)  1,854 
(6%) 
70.9 (68.2-73.4) 1,509 
(6%) 
81.6 (79.2-83.8)  
Thickness     <0.001     <0.001 
T1:≤1.00 mm 
11,543 
(70%) 
97.3 (96.9-97.7) 9,450 
(75%) 
98.6 (98.3-98.9)  18,897 
(61%) 
96.1 (95.8-96.5) 17,764 
(67%) 
98.0 (97.8-98.3)  
T2: 1.01-2.00 mm 
2,316 
(14%) 
82.5 (80.3-84.4) 1,598 
(13%) 
89.4 (87.4-91.1)  4,296 
(14%) 
82.7 (81.3-84.1) 3,262 
(12%) 
87.5 (86.0-88.8)  
T3: 2.01-4.00 mm 
1,434 
(9%) 
68.3 (65.0-71.3) 815 
(6%) 
75.2 (71.1-78.9)  2,457 
(8%) 
62.2 (59.7-64.6) 1,593 
(6%) 
73.9 (71.1-76.4)  
T4: >4.00mm 
759 
(5%) 
58.4 (53.7-62.8) 415 
(3%) 
66.5 (60.7-71.6)  1,310 
(4%) 
49.6 (46.2-52.9) 761 
(3%) 
59.8 (55.1-64.0)  
Unknown3 
374 
(2%) 
76.6 (71.2-81.1) 275 
(2%) 
82.8 (77.3-87.1)  4,037 
(13%) 
69.7 (68.1-71.3) 3,025 
(11%) 
81.4 (79.8-82.8)  
Body site     <0.001     <0.001 
Scalp/neck 
1,209 
(7%) 
81.2 (78.2-83.8) 563 
(4%) 
90.1 (86.5-92.8)  2,739 
(9%) 
79.8 (77.9-81.5) 949 
(4%) 
85.3 (82.3-87.8)  
Face/ears 
1,766 
(11%) 
87.6 (85.4-89.4) 1,081 
(9%) 
93.7 (91.6-95.2)  4,475 
(14%) 
88.1 (86.8-89.2) 2,253 
(9%) 
92.8 (91.4-94.0)  
Trunk 
7,227 
(44%) 
91.7 (90.9-92.4) 3,239 
(26%) 
94.9 (93.9-95.7)  12,510 
(40%) 
89.0 (88.3-89.6) 6,955 
(26%) 
93.1 (92.3-93.7)  
Upper limbs/shoulders 3,669 93.7 (92.7-94.6) 3,487 95.9 (95.0-96.6)  7,022 91.0 (90.2-91.8) 6,976 95.0 (94.4-95.6)  
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 Queensland (N=28,979) United States (SEER-9) (N=57,402) 
 Males Females  Males Females  
Sub-group N(%) 10 year Survival (95%CI) N 
10 year Survival 
(95%CI) P
1 N 10 year Survival (95%CI) N 
10 year Survival 
(95%CI) P
1 
(22%) (28%) (23%) (26%) 
Lower limbs 
2,410 
(15%) 
91.0 (89.5-92.3) 4,059 
(32%) 
94.8 (94.0-95.6)  3,023 
(10%) 
85.4 (83.9-86.9) 8,592 
(33%) 
93.6 (93.0-94.2)  
Not specified3 
145 
(1%) 
88.5 (81.9-92.8) 124 
(1%) 
90.0 (83.0-94.2)  1,228 
(4%) 
42.5 (39.4-45.6) 680 
(3%) 
49.8 (45.5-54.0)  
Histology     <0.001     <0.001 
SSM 
9,024 
(55%) 
94.6 (94.0-95.2) 7,385 
(59%) 
96.9 (96.4-97.4)  10,889 
(35%) 
93.0 (92.4-93.5) 10,615 
(40%) 
96.6 (96.1-96.9)  
NM 
1,529 
(9%) 
69.4 (66.5-72.0) 904 
(7%) 
79.3 (76.1-82.2)  2,291 
(7%) 
61.2 (58.7-63.6) 1,474 
(6%) 
74.9 (72.1-77.4)  
LMM 
1,039 
(6%) 
93.6 (90.8-95.6) 649 
(5%) 
98.2 (96.1-99.2)  2,620 
(8%) 
95.3 (94.0-96.3) 1,332 
(5%) 
98.5 (97.5-99.1)  
MOS 
1,078 
(7%) 
82.9 (79.4-85.9) 745 
(6%) 
89.9 (86.5-92.5)  1,609 
(5%) 
79.3 (76.7-81.6) 1,334 
(5%) 
86.4 (84.1-88.5)  
MNOS 
3,756 
(23%) 
91.5 (90.4-92.5) 2,870 
(23%) 
94.5 (93.5-95.4)  13,588 
(44%) 
84.2 (83.5-84.9) 11,650 
(44%) 
90.6 (90.0-91.3)  
Metastasis           
No metastasis 
16,333 
(99%) 
91.3 (90.7-91.8) 12,496 
(>99%) 
95.0 (94.6-95.5) <0.001 21,277 
(90%) 
89.3 (88.8-89.7) 18,420 
(94%) 
94.0 (93.6-94.3) <0.001 
Distant metastasis 
93 
(1%) 
21.0 (10.9-33.4) 57 
(<1%) 
37.6 (22.1-53.1)  2,328 
(10%) 
14.6 (11.8-17.7) 1,228 
(6%) 
20.8 (16.5-25.5)  
Unknown3 _4 
_4 _4 _4  7,392 
(24%) 
75.9 (73.0-78.5) 6,757 
(26%) 
85.7 (83.1-87.9)  
Nodal spread           
No positive nodes 
16,268 
(99%) 
91.4 (90.9-91.9) 12,470 
(99%) 
95.1 (94.6-95.5) <0.001 28,595 
(96%) 
90.5 (90.0-91.0) 24,792 
(98%) 
94.6 (94.1-95.0) <0.001 
At least one positive 
154 
(1%) 
32.2 (22.9-41.9) 79 
(1%) 
49.9 (36.7-61.8)  1,039 
(4%) 
46.6 (44.1-49.1) 492 
(2%) 
56.9 (53.5-60.1)  
Unknown3 _5 
_5 _5 _5  1,363 
(4%) 
86.4 (85.5-87.2) 1,121 
(4%) 
92.4 (91.7-93.0)  
AJCC Stage6     <0.001     <0.001 
Stage I 
12,799 
(83%) 
96.4 (96.0-96.8) 10,357 
(87%) 
98.1 (97.8-98.5)  16,754 
(75%) 
95.0 (94.5-95.4) 15,180 
(82%) 
97.0 (96.5-97.3)  
Stage II 
2,460 
(16%) 
67.5 (65.0-69.9) 1,414 
(12%) 
75.5 (72.5-78.1)  2,703 
(12%) 
66.6 (64.2-68.9) 1,800 
(10%) 
76.7 (74.0-79.1)  
Stage III-IV7 
223 
(1%) 
31.5 (23.7-39.6) 123 
(1%) 
48.5 (37.5-58.6)  2,821 
(13%) 
39.2 (36.9-41.5) 1,492 
(8%) 
49.0 (45.9-52.1)  
Unknown8 
944 
(6%) 
84.5 (81.5-87.8) 659 
(5%) 
89.5 (86.5-91.9)  8,719 
(28%) 
89.8 (89.1-90.5) 7,933 
(30%) 
94.5 (94.0-95.0)  
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CI: confidence interval; SSM (superficial spreading melanoma); NM (nodular melanoma); LMM (lentigo maligna melanoma); MOS (melanoma other 
specified); MNOS (melanoma not specified)  
 
1. P-values from log-rank test (all patients) or stratified log-rank test by sub-group for equality of survival functions between males and females. 
Please refer to text for details.  
2. Modeled as a continuous variable in the prognostic model 
3. Imputed values for missing data were estimated in the modeling process using multiple chained imputations. 
4. None in unknown category for Queensland cohort 
5. Number of cases is less than five.  Number of melanomas with nodes negative or node positive status was randomly adjusted by a small (<5) 
number to prevent confidentiality issues.  
6. Stage I: T1, N0, M0, without ulceration; Stage II: T1, N0, M0, with ulceration; T2-T4, N0, M0, with or without ulceration; Stage III: all T, N1, M0, 
with or without ulceration; Stage IV: all T, all N, M1, with or without ulceration. Stage categories based on American Joint committee on cancer 
(AJCC) seventh edition for melanoma.(12) 
7. Stage III and Stage IV melanomas combined due to small numbers. 
8. Replaced with stage obtained by combining the imputed values for missing thickness, ulceration, metastasis and nodal spread for each multiply 
imputed data set during the modelling process. 
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Table 2: Sex-related odds ratios for melanoma–specific mortality from flexible parametric survival models for Queensland and United States (SEER-
9) based cohorts according to tumour stage. 
 
Sub-group Variables in model (in addition to Gender) Queensland United States (SEER-9) 
  OR
1 (95%CI)  
Female : Male P
2 OR
1 (95%CI)  
Female : Male P
2 
All patients       
 Unadjusted 0.55 (0.50-0.61) < 0.001 0.51 (0.48-0.55) < 0.001 
 Age, site& stage3, 4 0.70 (0.62-0.79) < 0.001 0.71 (0.66-0.77) < 0.001 
 Age, site, thickness, nodes, metastasis & ulceration5 0.73 (0.64-0.82) <0.001 0.75 (0.69-0.80) <0.001 
Stage I4      
 Unadjusted 0.53 (0.42-0.66) < 0.001 0.57 (0.50-0.66) < 0.001 
 Age, site, thickness, nodes, metastasis & ulceration 0.64 (0.51-0.82) < 0.001 0.79 (0.68-0.92) < 0.001 
Stage II      
 Unadjusted 0.62 (0.52-0.75) < 0.001 0.59 (0.51-0.69) < 0.001 
 Age, site, thickness, nodes, metastasis & ulceration 0.71 (0.58-0.87) < 0.001 0.69 (0.59-0.82) < 0.001 
Stage III-IV6      
 Unadjusted 0.60 (0.39-0.91) 0.015 0.70 (0.62-0.79) < 0.001 
 Age, site, thickness, nodes, metastasis & ulceration 0.70 (0.44-1.10) 0.120 0.78 (0.68-0.90) < 0.001 
 
OR: odds ratio; CI: confidence interval 
 
1. Reference category is males 
2. P value from joint test of coefficients for multiple imputed data 
3. According to American Joint committee on cancer (AJCC) seventh edition stage for melanoma.(12) 
4. Reference category are melanomas of the trunk and stage I melanomas 
5. Reference categories are melanomas of the trunk, no nodal spread, no distant metastasis and no ulceration 
6. Stage III and IV melanomas combined due to small numbers 
 
!!! 95 
Table 3: Sex-related odds ratios for melanoma–specific mortality from flexible parametric survival models for Queensland and United States (SEER-
9) based cohorts according to age group. 
 
Sub-group Variables in model (in addition to Gender) Queensland United States (SEER-9) 
  N OR
1 (95%CI)  
Female : Male P
2 N OR
1 (95%CI)  
Female : Male P
2 
All patients        
Age 15-45 years  7,957   17,023   
 Unadjusted  0.58 (0.46-0.74) < 0.001  0.36 (0.32-0.41) < 0.001 
 Site, thickness, nodes, metastasis & ulceration4  0.73 (0.56-0.93) 0.018  0.64 (0.54-0.75) <0.001 
Age 46-59 years  8,140   17,347   
 Unadjusted  0.65 (0.52-0.81) < 0.001  0.51 (0.45-0.57) <0.001 
 Site, thickness, nodes, metastasis & ulceration  0.93 (0.73-1.12) 0.577  0.74 (0.64-0.86) < 0.001 
Age ≥60 years  12,882   23,032   
 Unadjusted  0.60 (0.52-0.69) <0.001  0.74 (0.68-0.81) <0.001 
 Site, thickness, nodes, metastasis & ulceration  0.66 (0.57-0.74) <0.001  0.77 (0.69-0.86) < 0.001 
Stage I4        
Age 15-45 years  4,707   9,489   
 Unadjusted  0.63 (0.40-0.97) 0.037  0.49 (0.36-0.65) < 0.001 
 Site, thickness, nodes, metastasis & ulceration  0.80 (0.51-1.17) 0.350  0.69 (0.51-0.95) 0.023 
Age 46-59 years  4,945   10,000   
 Unadjusted  0.64 (0.43-0.95) 0.026  0.60 (0.46-0.79) < 0.001 
 Site, thickness, nodes, metastasis & ulceration  0.81 (0.53-1.23) 0.327  0.84 (0.62-1.12) 0.234 
Age ≥60 years  6,860   11,933   
 Unadjusted  0.47 (0.33-0.67) <0.001  0.75 (0.62-0.92) 0.005 
 Site, thickness, nodes, metastasis & ulceration  0.43 (0.30-0.63) <0.001  0.75 (0.60-0.94) 0.011 
Stage II        
Age 15-45 years  395   837   
 Unadjusted  0.55 (0.33-0.92) 0.023  0.56 (0.38-0.81) 0.002 
 Site, thickness, nodes, metastasis & ulceration4  0.56 (0.33-0.98) 0.042  0.67 (0.45-0.94) 0.044 
Age 46-59 years  599   1,107   
 Unadjusted  0.75 (0.50-1.15) 0.187  0.57 (0.41-0.76) < 0.001 
 Site, thickness, nodes, metastasis & ulceration  0.95 (0.61-1.49) 0.821  0.59 (0.43-0.82) 0.002 
Age ≥60 years  2,124   2,508   
 Unadjusted  0.61 (0.49-0.76) <0.001  0.68 (0.55-0.83) <0.001 
 Site, thickness, nodes, metastasis & ulceration  0.70 (0.55-0.89) 0.004  0.75 (0.60-0.93) 0.010 
Stage III-IV        
Age 15-45 years  76   1,181   
 Unadjusted  0.82 (0.35-1.95) 0.655  0.53 (0.42-0.68) < 0.001 
 Site, thickness, nodes, metastasis & ulceration  0.88 (0.30-2.58) 0.818  0.71 (0.54-0.93) 0.013 
Age 46-59 years  81   1,292   
 Unadjusted  1.30 (0.85-3.05) 0.545  0.71 (0.57-0.89) 0.003 
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Sub-group Variables in model (in addition to Gender) Queensland United States (SEER-9) 
  N OR
1 (95%CI)  
Female : Male P
2 N OR
1 (95%CI)  
Female : Male P
2 
 Site, thickness, nodes, metastasis & ulceration  1.76 (0.66-3.80) 0.227  0.86 (0.67-1.01) 0.013 
Age ≥60 years  189   1,840   
 Unadjusted  0.43 (0.23-0.78) 0.005  0.81 (0.67-0.97) 0.019 
 Site, thickness, nodes, metastasis & ulceration  0.46 (0.24-0.87) 0.017  0.76 (0.62-0.94) 0.010 
 
OR: odds ratio; CI: confidence interval 
 
1. Reference category is males  
2. P value from joint test of coefficients for multiple imputed data 
3. Reference categories are stage I melanomas and melanomas of the trunk. 
4. Reference categories are melanomas of the trunk, no nodal spread, no distant metastasis and no ulceration 
5. American Joint committee on cancer (AJCC) seventh edition stage for melanoma.(12). Stage III and IV combined due to small number 
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General Discussion 
Whilst the female survival benefit is well known, the underlying mechanisms are not. We here 
demonstrated that this survival benefit is dependent on age at diagnosis further supporting an 
underlying biological mechanism. The greatest survival benefit was in post-menopausal women, 
those aged over the age of 60. This is a cohort of women who have completed their families and 
would have the highest proportion of parous females of all age groups. Thus the question is raised 
again whether parity represents a protective influence for melanoma outcome.  
 
The relative survival advantage of females over males may be explained by a combination of 
protective influence of female hormones and the detrimental effect of male hormones. Further 
studies are required to directly explore the effect of sex hormones on the tumour and its 
environment. Understanding the role of sex hormones in both melanoma progression and outcome 
will allow for development of better-targeted therapies. 
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CHAPTER 6  
Discussion and conclusion 
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There are well-established differences in melanoma outcome according to the sex of the patient. 
The female survival benefit for melanoma has been demonstrated across European (15, 102), 
American (chapter 5), and Australian (chapter 5) cohorts. This may be explained by the differences 
in host-factors between the sexes throughout the lifespan. This includes pregnancy-associated 
factors, sex hormones, and behavioural factors. However, as this survival benefit persists across all 
stages despite adjustment for known prognostic factors, including patient age and melanoma stage, 
behavioural differences between the genders alone are unlikely to explain the female survival 
advantage. A protective influence in females has been postulated, however, the mechanisms 
underlying this are still being investigated. The exposure to a pregnancy is associated with negative 
outcomes for a coinciding melanoma in females. Despite this overall the female survival benefit in 
melanoma persists.  
 
Melanomas often differ between males and females in a number of characteristics upon diagnosis. 
In this study (chapter 5), adjustment for such factors such as Breslow thickness or site of the 
primary tumour that significantly differed between males and females reduced but did not eliminate 
the survival benefit observed in females. This reduction might reflect the influence of behavioural 
factors resulting in diagnostic delays and possibly thicker melanomas in males (129). However, 
despite adjusting for a wide range of confounding factors the survival benefit in females remained 
significant across nearly all tumour stage categories supporting previous reports in European 
cohorts (15, 89, 102). However, the survival advantage demonstrated in thin melanomas (chapter 5) 
had not previously been explored in detail (15, 102). This indicated that the survival benefit 
observed in females might have an additional biological explanation. 
 
This difference may be explained by reproductive factors such as pregnancy and parity. These are 
biological factors that only females are exposed to thus may assist in explaining the female survival 
benefit. A recent study showed that females with at least one pregnancy had improved melanoma 
survival rates compared to nulliparous females when adjusted for age, localisation, stage, and 
Breslows thickness (34). This was not reproduced in the Queensland cohort (chapter 4). However, 
despite having a long follow-up time, this was a small sample size therefore lacked statistical power 
required to identify any potential effect of parity on melanoma outcome. The fact that the female 
survival advantage seemed stronger in women past 60 years old (chapter 5) could be in favour of 
this hypothesis. 
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The possible benefit of past pregnancy on melanoma could arise as a result of fetal maternal 
chimerism (99). During pregnancy, there is a natural transfer of fetal cells in maternal circulation 
and tissues that can persist for decades. Recently, studies have shown a reduced number of fetal 
cells in females with cancer suggesting a loss of this protective benefit (130). The immune 
consequences of this phenomenon are unknown and still under investigation. A study by Nguyen et 
al (99) demonstrated the presence of fetal cells in 63% of human primary melanomas occurring 
during pregnancy compared to 12% nevi. These semi-allogenic fetal cells could potentially react 
against maternal tissues including tumours, therefore, asserting a protective mechanism as 
previously shown in breast cancer (100). 
 
An alternate hypothesis is the change of phenotype of melanocytes into a less invasive cell type 
through pregnancy. It is currently debated whether melanoma has a specific cancer stem cell or is 
the result of cells which switch their phenotype from a tumour forming highly proliferative type to 
an invasive highly mobile type depending on their environment (131). This hypothesis that 
pregnancy might predispose melanocytes that will later generate a melanoma or their environment 
to become less invasive remains entirely speculative and requires further research.  
 
It has been previously proposed that estrogens have positive influence on melanoma outcome (46). 
Melanoma cells express estrogen receptor beta, an anti-proliferative receptor for estrogens (65), 
which is inversely correlated with melanoma thickness (124). Additionally, estrogen receptor beta 
was more likely to be expressed in melanomas of females compared to males (125). The loss of 
expression of estrogen receptor beta is also correlated with increased tumour invasiveness (65). The 
treatment of melanoma with Tamoxifen, an estrogen receptor antagonist, has not shown any benefit 
in terms of overall survival (67, 68). This suggests that once melanoma develops, its progression 
might not be linked to estrogens.  A study by Li et al (66) demonstrated that 25.7% of their 
melanoma patients had progesterone receptors expressed in melanoma cells compared to no 
expression in nevi, but this difference was not statistically significant. They did demonstrate a 
significant inverse correlation between progesterone receptor expression and proliferative nuclear 
antigen expression, suggesting that progesterone receptor expression in melanoma may be 
correlated with decreased tumour growth. These reports collectively support an important role of 
female sex hormones in the development and progression of melanoma. However, the significance 
of this for melanoma management is not clear. 
 
An alternative biological explanation of the female survival advantage may lay in the negative 
influence of male androgens play a role in the female survival advantage in melanoma. Male sex 
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hormones have been demonstrated to play a role in the development and progression of melanoma. 
Testosterone, dihydrotestosterone (DHT), and dehydroepiandrosterone (DHEA) are some of the 
main androgens in the male systemic circulation (132). All have been demonstrated to stimulate 
melanoma cell proliferation and enhance tumour invasion in animal models (126-128). 
Additionally, treatment of melanomas in male mice with anti-androgen therapy led to increased 
survival (128). These experimental models are supported by recent epidemiological evidence 
linking androgen-related disorders, such as prostate cancer, to melanoma incidence although 
survival has not been considered (133). Over the course of the male lifespan androgen levels 
gradually decrease, however, this runs contrary to the known deterioration in prognosis with age 
(95, 134, 135). Interestingly, the levels of androgens increase during pregnancy, which might be an 
additional explanation of the worse outcome (136). Further studies should directly explore the role 
of sex hormones, not only in females but also in males, in relation to melanoma prognosis. 
 
There are a number of pregnancy-associated factors that have been reported to influence the 
prognosis of melanoma as well as other solid cancers. In particular, proliferation, resistance to 
apoptosis, tumour vascularisation, and escaping the immune system are common mechanisms 
important for tumour progression (Weinberg hallmarks of cancer). Although not well understood, 
there are similarities between the progression of cancer and the physiological process of pregnancy 
(72, 77). For cancer to metastasise the tumour cells need to have the ability to establish a 
relationship with the host tissues allowing their survival and proliferation. Pregnancy is a state of 
reduced cellular immunity that is necessary to prevent rejection of the fetus. In animal models, 
gestation is associated with decreased natural killer cell cytotoxicity in the presence of increased 
myeloid-derived suppressor cell population leading to increased metastases (57). This may 
represent the mechanism of immune suppression during gestation leading to enhanced tumour 
growth and metastatases. Additional to the changes to the immune system during gestation there are 
also increases in circulating hormones such as estrogen, progesterone, and prolactin compared with 
the non-pregnant state.  
 
The effect of pregnancy-associated hormones on melanoma is a topic of ongoing research. The 
presence of both estrogen and progesterone receptors on melanoma cells have been associated with 
decreased tumour proliferation (65, 66). Prolactin has been shown to have an anti-tumour effect 
resulting in reduced metastases and improved survival in animal studies (137, 138). Conversely, 
high levels of prolactin is correlated with poorer outcomes in breast cancer patients (139). However, 
this has not been demonstrated in melanoma. In a recent experiment, it was shown that primary 
melanomas occurring during gestation, despite having more lymphangiogenesis, did not seem to 
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harbor excessive prolactin signaling as measured by proportion of Phospho-STAT5 positive tumour 
components (63). Thus evidence to date suggests that pregnancy-associated hormones per se do not 
influence the natural course of melanoma.  
 
It is possible that pregnancy-associated hormones alone do not have an effect on the progression of 
melanoma during pregnancy, but in fact it may be due to the interplay between hormones and the 
immune system. Pregnancy-associated hormones, such as estrogen and progesterone, play an 
important role in modulating the immune system in both cancer and pregnancy (74). Immune cells 
such as natural killer cells, macrophages, and lymphocytes, all express estrogen receptors thus are 
regulated by estrogen (140). Low levels of progesterone inhibit natural killer cells during pregnancy 
compared to higher levels required in the non-pregnant state (141). The implications for melanoma 
management are still under investigation. 
 
The relationship between pregnancy-associated hormones and growth factors may enable 
pregnancy progression. Pro-angiogenic factors, including vascular endothelial growth factor 
(VEGF) and placental growth factors (including human chronic gonadotropin), are released during 
pregnancy and are expressed in melanomas (142). Human chronic gonadotropin, secreted by both 
the placenta and melanoma (143), both prevents apoptosis and stimulates angiogenesis (144, 145). 
Estrogen stimulates VEGF production and angiogenesis, which is essential for the establishment 
and development of the fetus. In early pregnancy, the trophoblast has an increased need for 
lymphangiogenesis, which in turn promotes the growth and progression of a coinciding melanoma 
(146).  It was recently reported that lymphangiogenesis associated with melanoma is dramatically 
enhanced during gestation, in both mice and humans, resulting in increased metastases in an animal 
model (61, 62). Tumour lymphangiogenesis is an important prognostic indicator for both overall 
survival and disease-free survival (60, 61, 147). This increased lymphangiogenesis occurring during 
pregnancy could plausibly worsen the outcome for melanomas occurring during gestation.  
 
Finally, the observation of physiological changes in colour and shape of melanocytic nevi during 
pregnancy has added to the hypothesis formulation that there is an effect of pregnancy-associated 
factors on melanocytic lesions. A study by Pennoyer et al (148) monitored melanocytic nevi in 22 
pregnant females. They photographed the nevi in the 1st and 3rd trimesters. Only nevi on the back 
were included due to the potential influence of signs of stretching on other body areas. 6.3% of 
melanocytic nevi changed diameter between the 1st and 3rd trimester. A prospective study of 47 
pregnant females evaluated melanocytic nevi located on the back in 1st trimester, 3rd trimester, and 6 
months postpartum (149). They demonstrated a decrease in global pigmentation and a less 
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prominent network in melanocytic nevi with progression of a pregnancy. Additionally, there were 
increased vascular structures observed during pregnancy that regressed post-partum. There was no 
significant change in dimensions of the nevi. In contrast, a number of studies have reported that 
melanocytic nevi increase in size and pigmentation during pregnancy (150, 151). It has been argued 
that these physiological changes in most naevi may delay a diagnostic biopsy on a suspicious 
lesions resulting in more invasive melanomas. Whether the changes in melanocytic nevi during 
pregnancy represent normal physiological change or are due to the effects of pregnancy-associated 
factors, such as hormones and growth factors, is still under investigation. 
 
Clinical implications  
The identification of a relationship between melanoma and pregnancy may improve the prediction 
of outcome and enable better management and counseling of females with melanoma. I have shown 
that melanomas occurring during pregnancy are associated with poorer disease specific mortality. 
Additionally, I have demonstrated that there are no firm grounds to delay a pregnancy for a thin 
melanoma survivor. However, evidence is sparse, suggesting a precautionary approach is warranted 
regarding childbearing advice to melanoma survivors. This is the most important limitation to 
translating my findings into clinical practice. The international guidelines for melanoma 
management are unclear on these two topics. Neither the 2011 American Academy of Dermatology 
guidelines of care for the management of primary cutaneous melanoma (42) nor the 2012 European 
Dermatology Forum guidelines for melanoma management (43) state any recommendations 
regarding management of melanomas occurring during pregnancy; nor do they provide advice on 
the timing of subsequent pregnancies. Current clinical practice guidelines for the management of 
melanoma in Australia and New Zealand (44) state that there is no effect of pregnancy on 
melanoma prognosis but also recommend that females avoid pregnancy for two to five years 
following diagnosis of a high-risk melanoma. However, no guidelines are provided for localized 
melanomas.  This precautionary advice reflects the uncertainty that exists around this question.  
 
The results of chapter 2 and 3 contain important information to a melanoma survivor who is yet to 
start her family, females who are at a high risk of developing melanoma, and the clinicians 
managing this group of females. I recommend that females with a previous melanoma be given a 
full skin exam prior to a planned pregnancy as well as regular full skin exams in the antenatal and 
post-natal period due to their increased risk of developing a second melanoma and the demonstrated 
poor outcomes of melanomas diagnosed during pregnancy.  Females with a treated localised 
melanoma have no firm grounds for delaying their childbearing plans. In comparison, a female who 
has had an advanced melanoma should be guided by known prognostic factors, such as melanoma 
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thickness and tumour stage, when considering a future pregnancy. Patients who are known to be at 
an increased risk of melanoma death, such as females who are diagnosed with melanoma during 
pregnancy and males, should be considered as high risk for their melanoma stage when 
implementing follow-up regimes. 
 
The identification of factors that impact the natural course of melanoma is the first step to 
improving and developing available management options. An improved understanding of 
mechanisms underlying the sex differences in melanoma outcome as well as the immuno-
modulatory effects of sex hormones, including during pregnancy, will allow for development of 
better targeted therapies for melanoma treatment.  
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